LOS ANGELES, CA–(Marketwire – August 26, 2010) – MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) is a sponsor of The Gulf is Back,  a one-hour TV special on the CW Network airing this Friday, August 27, 2010, at 8:00 p.m. ET. The Company believes the sponsorship of the special tribute, hosted by David Hasselhoff and featuring musical performances by Lonestar, Ricky Skaggs, Taylor Hicks and Brian McKnight, will help call attention to the importance of having a MyMedicalRecords Personal Health Record account (www.mmrvideos.com) or MyEsafeDepositBox online safe (www.myesafevideos.com) in the event of a disaster or emergency at home or anywhere in the world.

Robert H. Lorsch, MMRGlobal Chairman and Chief Executive Officer, said, “We are proud to be a sponsor of Associated Television International’s network television special The Gulf is Back. People experiencing a personal or business loss need access to the important documents necessary to rebuild their lives. Our products offer the reliability and resiliency needed to recover more quickly from any emergency or disaster. With MyMedicalRecords, individuals and families can have direct access to their most important documents, including insurance policies, deeds of trust, wills, birth certificates and advance directives in addition to their medical records. Everything is located in one secure, convenient location accessible from any Internet device anywhere in the world.”

Viewers responding to the MyMedicalRecords TV spots on The Gulf is Back will be greeted with the same onscreen technology used for the Daytime Emmy Awards last June. However, in addition to fulfilling requests for information, consumers who sign up for a free trial account can participate in the MMRGlobal $25 cash refund program applied to the viewer’s next check-up or doctor visit.

MMRGlobal’s advertising campaigns can be previewed at www.mmrontv.com. 

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, television programming changes, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

BOCA RATON, FL–(Marketwire – August 26, 2010) –  David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that abstracts of three studies involving its PD2i^® nonlinear algorithm have been accepted for presentation during the Poster Session of the 2010 Heart-Brain Summit. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

“We’re honored to have three abstracts selected for presentation before this prestigious group, especially during the distinguished Poster Session. We believe the results achieved by the PD2i^® in each of these studies suggest the prospect of incorporating the PD2i^® nonlinear algorithm into a noninvasive diagnostic that will significantly contribute to the identification and treatment of at-risk patients. We hope that having the opportunity to share these results with those active in the field of heart-brain medicine worldwide will further opportunities to advance study of the PD2i^® as a noninvasive diagnostic to identify at-risk populations and further our commercialization efforts for the PD2i^®,” stated Mr. Fater.

Dr. James E. Skinner, Vicor Vice President and Director of Grant Research, will present the following abstracts at the 2010 Heart-Brain Summit, which will be held at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, September 23-24. The Poster Session is on September 23, from 5:00 to 7:00pm.

Short-Term Heart Rate Complexity Determined by the PD2i^® Algorithm is Reduced in Patients with Type 1 Diabetes Melitus — The objective of this study was to test the ability of PD2i^® to discriminate between young DM patients without neuropathy and age- and gender-matched controls. Seventeen DM patients with known autonomic dysfunction and 17 age- and gender-matched controls were studied. The same R-R interval data (3,200 heartbeats per subject) were analyzed (blinded) to determine the PD2i^® values. The study revealed that the PD2i^® was able to detect ANS dysfunction with p = 0.0006.

Prognostic Significance of PD2i^® in Heart Failure Patients — The goal of this effort was to determine the PD2i^®‘s ability to predict cardiac events in chronic heart failure patients. The study population was a group of chronic heart failure patients, who had been studied for 44 months, on average, with total mortality as primary endpoint and cardiac mortality, sudden cardiac death, and heart failure death as secondary endpoints. The PD2i^® was computed based on 20-minute supine high-resolution Holter recording and was categorized as positive (PD2i® less than or equal to 1.4) or negative (pD2i® greater than 1.4) based on pre-specified criteria. Of the 651 chronic heart failure patients studied, 537 had successful PD2i^® analyses resulting in 144 (27%) patients showing positive results and 393 (73%) negative results. After adjustment for clinical covariates PD2i^®, was found predictive for total mortality (HR=1.55; p=0.026). Predictive value of PD2i^® was observed in heart failure patients with left ventricular ejection fraction less than or equal to 35% (HR=1.95; p=0.004) whereas not in patients with greater than 35% (HR=0.87; p=0.716); p for interaction 0.072. Further analyses revealed that among patients with ejection fraction less than or equal to 35%, PD2i^® was also predictive for cardiac death and for heart failure death.

Mild Hypovolemia and PD2i^® — The goal of this pilot study was to test the ability of the PD2i^® to identify acute hypovolemia in blood donors as a preliminary step toward ascertaining whether it could be a useful noninvasive diagnostic for detecting blood loss from internal bleeding. Study subjects were volunteers who presented for a standard single unit whole blood donation. A 15-minute ECG recording was made pre-donation and the recording was then continued during the donation period and a rest afterwards. Eighteen subjects participated with a mean age of 48+/-18 years. Three were on beta blockers, 2 on antidepressants, and 1 had diabetes. At baseline the minimum PD2i^® had a mean of 2.6+/-0.8 dimensions, whereas after donation it fell to 1.8+/-0.5 dimensions (p=0.0011). The minimum PD2i^® was found to be a sensitive metric for the detection of mild blood loss, as seen in the controlled environment of donation of a whole unit of blood. Thus, PD2i^® may serve as a marker for mild hemorrhage in hospital (e.g., surgery) and trauma environments. In addition, given PD2i^®‘s association with autonomic activity, these results suggest significant sympathetic activation with even standard blood donation, suggesting that PD2i^® can be used to track a patient’s autonomic response to insult.

The Heart-Brain Summit, now in its fifth year, is the annual event of The Society for Heart Brain Medicine. More than 200 physicians, researchers, scientists, and industry professionals from around the world attended the 4^th Annual Heart-Brain Summit in 2009.

The Society for Heart Brain Medicine was officially established as a 501(c) (3) organization in June of 2008, with the purpose of:

• educating clinicians and scientists about the physiology, pathophysiology, and medical aspects of heart-brain interactions;
• educating the public about these aspects; and
• promoting and fostering research into heart-brain relationships.

The Society for Heart-Brain Medicine provides a forum for researchers and clinicians from different disciplines, both clinical and laboratory, to present, discuss, and evaluate data, and promotes the study of heart-brain medicine as a discipline in its own right. Additional information about the Society for Heart-Brain Medicine is available at www.heartbrain.org.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense, the U.S. Government, or the AABB of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Click here to see all recent news from this company

BUENA PARK, CA–(Marketwire – August 26, 2010) –  SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced that it has posted a 1,000 percent year-over-year increase in revenue for the second quarter ending June 30, 2010. Due to successive record quarters and the company’s unprecedented corporate revenue growth the Company expects continued consumer adoption of its private label generic pharmaceutical products. Revenues for the three months ended June 30, 2010 increased over 1,000% to $339,545 compared to $33,599 in the second quarter of 2009. Revenue growth was fueled by expansion of current and new clients and from pilot distribution projects to full production deployments.

Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc., stated, “Our ability to generate record revenue growth and accelerated consumer adoption rates for our generic pharmaceutical products is a direct reflection of our sales and marketing team’s dedication. We continue to demonstrate our ability to penetrate and lead in our chosen emerging markets. Most significantly, SOHM has grown and matured its generic drug manufacturing operations allowing for the scalability of resources and product production necessary to support a growing worldwide customer base.”

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters are located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

HOUSTON, TX–(Marketwire – August 25, 2010) –  Over the next three days, the Discovery Channel will begin airing a special episode of Health Heroes focused on dental innovations, including a segment on clear aligner therapy. The episode educates viewers about clear aligner therapy, a popular teeth-straightening alternative to metal braces, and also explores how orthodontic manufacturers such as ClearCorrect are making the procedure simpler and more affordable to the public. 

The episode premieres on both the East and West Coast at 7 am on Thursday, August 26, 2010 on the Discover Channel. It will re-air on Dish Network Channel 225 on Friday, August 27, 2010 at 10 pm EDT and on the Discovery Channel via DirectTV on Saturday, August 28, 2010 at 10 pm EDT.

Clear aligner therapy is an orthodontic treatment involving a series of clear, removable aligners that gradually move teeth to improve aesthetics and bite function. The technique, often referred to as “invisible braces,” is becoming increasingly popular with the public and a key growth area for dentists looking to add services.

The Health Heroes episode features dental industry innovators, including ClearCorrect founder Willis Pumphrey, DDS, and how he, along with input from other dentists, worked to create a more patient and doctor-friendly alternative to more costly clear aligner choices on the market.

In the clear aligner process, ClearCorrect receives the patient’s records from their general dentist or orthodontist and creates exact 3D models of the teeth. Working with a doctor, ClearCorrect then maps out a complete treatment plan of gradual adjustment, then manufacturers and delivers the clear aligners used in the procedure. 

For doctors interested in learning more about clear aligner therapy, ClearCorrect will be at two upcoming dental conventions. It will be at the California Dental Association (CDA) convention in San Francisco, CA on September 9-11, 2010 at Booth # 736 and at the American Dental Association (ADA) convention in Orlando, FL on October 9-11, 2010 at Booth #1244.

For more info, call 888-331-3323 toll free; visit www.clearcorrect.com; or write to ClearCorrect, Inc. at 5200 Mitchelldale St., Suite F-26, Houston TX 77092.

NASHVILLE, TN–(Marketwire – August 25, 2010) – Vanguard Health Systems, Inc. (Vanguard)
today announced results for the fourth quarter and fiscal year ended June
30, 2010.

Total revenues for the quarter ended June 30, 2010 were $858.4 million, an
increase of $31.9 million or 3.9% from the prior year quarter. Patient
service revenues increased $17.4 million from the prior year quarter.
Health plan premium revenues increased $14.5 million from the prior year
quarter. The increase in patient service revenues was attributable to a
3.3% increase in adjusted discharges offset by a 0.2% decrease in patient
revenue per adjusted discharge during the current year quarter compared to
the prior year quarter. Absent the implementation of an insured discount
policy in our Phoenix and San Antonio hospitals effective July 1, 2009,
similar to the program implemented in our two Illinois hospitals on April
1, 2009, and a change to the Medicaid pending policy at all of our
hospitals, patient revenue per adjusted discharge would have increased 3.2%
during the current year quarter compared to the prior year quarter. The
increase in health plan premium revenues was primarily attributable to a
17.1% increase in average membership in Phoenix Health Plan (PHP) during
the current year quarter compared to the prior year quarter. Economic
conditions in Arizona continue to increase the number of individuals
eligible for coverage under the Arizona Health Care Cost Containment System
(AHCCCS) and thus expand PHP’s membership.

Vanguard reported income from continuing operations of $3.4 million for the
current year quarter compared to $2.1 million during the prior year
quarter. During the current year quarter, Vanguard’s net income
attributable to Vanguard Health Systems, Inc. stockholders was $2.8 million
compared to $1.8 million during the prior year quarter. Many quarter over
quarter comparisons of individual cost and expense items, particularly for
health plan claims expense and the provision for doubtful accounts, as a
percentage of total revenues during the current year quarter were impacted
by the significant growth in health plan premium revenues and the uninsured
discount and Medicaid pending policy changes. A table describing the impact
of adjustments to certain expenses and revenues and related ratios for our
acute care services segment and to certain statistical measures is included
in this release in the attached Supplemental Operating Measures Adjusted
for Comparative Analysis.

Adjusted EBITDA for the current year quarter was $82.9 million, an 11.3%
increase compared to the prior year quarter. A reconciliation of Adjusted
EBITDA to net income (loss) attributable to Vanguard Health Systems, Inc.
stockholders as determined in accordance with generally accepted accounting
principles for the quarters ended June 30, 2009 and 2010 is included in the
attached supplemental financial information.

The consolidated operating results for the current year quarter reflect a
1.8% increase in discharges and a 3.3% increase in adjusted discharges
compared to the prior year quarter. Emergency room visits increased 1.0%,
while inpatient surgeries and outpatient surgeries decreased 3.0% and 2.2%,
respectively, during the current year quarter compared to the prior year
quarter. General economic weakness in the United States economy continues
to impact demand for elective surgical procedures.

Total revenues for the year ended June 30, 2010 were $3,376.9 million, an
increase of $191.5 million or 6.0% from the prior year. Patient service
revenues and health plan premium revenues increased $29.8 million and
$161.7 million, respectively, from the prior year. Total revenues during
the current year were positively impacted by a 2.4% increase in adjusted
discharges but were negatively impacted by a 1.1% decrease in patient
revenue per adjusted discharge compared to the prior year. Absent the
previously discussed uninsured discount and Medicaid pending policy
changes, patient revenue per adjusted discharge would have increased 2.8%
during the current year compared to the prior year. Health plan premium
revenues increased 23.8% during the current year primarily due to the
significant enrollment increase associated with PHP’s new contract with
AHCCCS that went into effect on October 1, 2008.

Vanguard reported a loss from continuing operations of $44.6 million during
the current year compared to income from continuing operations of $32.1
million during the prior year. Net loss attributable to Vanguard Health
Systems, Inc. stockholders for the current year was $49.2 million compared
to net income attributable to Vanguard Health Systems, Inc. stockholders of
$28.6 million during the prior year. Each of these current year measures
was negatively impacted by the goodwill impairment loss related to our
Illinois hospitals recognized in December 2009 and by debt extinguishment
costs incurred to complete a refinancing of our indebtedness in January
2010. Many year over year comparisons of individual cost and expense items
as a percentage of total revenues, particularly for health plan claims
expense and the provision for doubtful accounts, were impacted by the
significant growth in health plan premium revenues and the uninsured
discount and Medicaid pending policy changes previously discussed. The
Supplemental Operating Measures Adjusted for Comparative Analysis table
included elsewhere in this release sets forth the impact of the uninsured
discount and Medicaid pending policy changes to certain expenses and
revenues and related ratios for our acute care services segment and to
certain statistical measures. Health plan claims expense as a percentage of
health plan premium revenues increased to 79.3% during the current year
compared to 77.5% during the prior year primarily as a result of changes to
capitation and supplemental payment rates, enrollee medical costs and
enrollee demographic mix under PHP’s new contract with AHCCCS that went
into effect on October 1, 2008.

Adjusted EBITDA was $326.6 million for the current year, an increase of
$23.9 million or 7.9% from the prior year. A reconciliation of Adjusted
EBITDA to net income (loss) attributable to Vanguard Health Systems, Inc.
stockholders as determined in accordance with generally accepted accounting
principles for the years ended June 30, 2009 and 2010 is included in the
attached supplemental financial information.

Cash flows from operating activities were $315.2 million for the current
year, an increase of $2.1 million from the prior year. Current year
operating cash flows were negatively impacted by AHCCCS’ deferral of the
June 2010 capitation and supplemental payments to PHP of approximately
$62.0 million until July 2010. Current year operating cash flows were
positively impacted by an improvement in net days revenue in accounts
receivable from 45 days at June 30, 2009 to 41 days at June 30, 2010. Cash
flows from operating activities were also positively impacted by the timing
of payments of accounts payable during the current year compared to the
prior year. Vanguard’s cash and cash equivalents balance was $257.6 million
at June 30, 2010 compared to $308.2 million at June 30, 2009.

On June 10, 2010, Vanguard entered into a definitive agreement to purchase
Detroit Medical Center (DMC), which owns and operates eight hospitals in
and around Detroit, Michigan with 1,734 licensed beds. Under the purchase
agreement, Vanguard will acquire all of DMC’s assets (other than donor
restricted and certain other assets) and assume all of its liabilities
(other than its outstanding bonds and other certain liabilities) for $417.0
million in cash, substantially all of which will be used to repay all such
non-assumed debt. The acquisition is pending review and approval by the
Michigan Attorney General. Detailed information regarding the purchase
price, assets acquired, liabilities assumed and future commitments related
to the DMC purchase are set forth in Vanguard’s Form 8-K filed with the
Securities and Exchange Commission on June 15, 2010. If approval is
obtained, Vanguard expects the DMC transaction to close during its second
quarter of fiscal 2011.

On July 14, 2010, certain of Vanguard’s subsidiaries issued $225.0 million
aggregate principal amount of 8% Senior Notes due 2018 (the Add-On Notes)
utilizing the same indenture governing the $950.0 million 8% Senior Notes
previously issued in January 2010. The Add-On Notes were issued at an
offering price of 96.250% plus accrued interest from January 29, 2010. The
proceeds from the issuance of the Add-On Notes will be used to fund a
portion of the DMC purchase price if such acquisition is approved by the
Michigan Attorney General or else used for general corporate purposes
including other potential acquisitions. Additional information regarding
the Add-On Notes is set forth in Vanguard’s Form 8-K filed with the
Securities and Exchange Commission on July 19, 2010.

On August 1, 2010, Vanguard completed the purchase of Westlake Hospital and
West Suburban Medical Center in the western suburbs of Chicago, Illinois
from Resurrection Health Care. As part of the purchase, Vanguard acquired
certain assets and assumed certain liabilities of these hospitals for a
total cash purchase price of approximately $45.0 million. These hospitals
have a combined 459 licensed beds and are each located within 10 miles of
Vanguard’s MacNeal Hospital. Additional information related to this
acquisition is set forth in Vanguard’s Form 8-K filed with the Securities
and Exchange Commission on August 4, 2010.

Vanguard will host a conference call for investors at 11:00 am EDT on
August 26, 2010. All interested investors are invited to access a live
audio broadcast of the call, via webcast. The live webcast can be accessed
on the home page of Vanguard’s Web site at www.vanguardhealth.com by
clicking on “Fourth Quarter Webcast” or at
http://visualwebcaster.com/event.asp?id=71303. If you are unable to
participate during the live webcast, the call will be available on a replay
basis on Vanguard’s Web site www.vanguardhealth.com. To access the replay,
click on the Investor Relations of www.vanguardhealth.com. The replay will
be available via this link for one year.

Vanguard owns and operates 17 acute care hospitals and complementary
facilities and services in Chicago, Illinois; Phoenix, Arizona; San
Antonio, Texas; and Massachusetts. Vanguard’s strategy is to develop
locally branded, comprehensive healthcare delivery networks in urban
markets. Vanguard will pursue acquisitions where there are opportunities to
partner with leading delivery systems in new urban markets or to increase
its presence in existing markets. Upon acquiring a facility or network of
facilities, Vanguard implements strategic and operational improvement
initiatives including expanding services, strengthening relationships with
physicians and managed care organizations, recruiting new physicians and
upgrading information systems and other capital equipment. These strategies
improve quality and network coverage in a cost effective and accessible
manner for the communities Vanguard serves.

This press release contains forward-looking statements within the meaning
of the federal securities laws, which are intended to be covered by the
safe harbors created thereby. These forward-looking statements include all
statements that are not historical statements of fact and those statements
regarding Vanguard’s intent, belief or expectations. Do not rely on any
forward-looking statements as such statements are subject to numerous
factors, risks and uncertainties that could cause Vanguard’s actual
outcomes, results, performance or achievements to be materially different
from those projected. These factors, risks and uncertainties include, among
others, Vanguard’s high degree of leverage and interest rate risk;
Vanguard’s ability to incur substantially more debt; operating and
financial restrictions in Vanguard’s debt agreements; Vanguard’s ability to
successfully implement its business strategies; Vanguard’s ability to
successfully integrate any future acquisitions; conflicts of interest that
may arise as a result of Vanguard’s control by a small number of
stockholders; the highly competitive nature of the healthcare business;
governmental regulation of the industry including Medicare and Medicaid
reimbursement levels; changes in Federal, state or local regulation
affecting the healthcare industry; the currently unknown effect on us of
the major federal healthcare reforms enacted by Congress in March 2010 or
other potential additional federal or state healthcare reforms; pressures
to contain costs by managed care organizations and other insurers and
Vanguard’s ability to negotiate acceptable terms with these third party
payers; the ability to attract and retain qualified management and
personnel, including physicians and nurses; claims and legal actions
relating to professional liabilities or other matters; the impacts of a
prolonged economic recession and tightened credit and capital markets on
Vanguard’s results of operations, financial position and cash flows
including its ability to successfully service its debt and remain in
compliance with debt covenants under its senior secured credit agreement;
Vanguard’s exposure to the increased amounts of and collection risks
associated with uninsured accounts and the co-pay and deductible portions
of insured accounts; Vanguard’s ability to maintain or increase patient
membership and control costs of its managed healthcare plans; the
availability and terms of capital to fund the expansion of Vanguard’s
business; the geographic concentration of Vanguard’s operations; the
technological and pharmaceutical improvements that increase the cost of
providing healthcare services or reduce the demand for such services; the
timeliness of reimbursement payments received under government programs;
the potential adverse impact of known and unknown government
investigations; and those factors, risks and uncertainties detailed in
Vanguard’s filings from time to time with the Securities and Exchange
Commission, including, among others, Vanguard’s Annual Reports on Form 10-K
and its Quarterly Reports on Form 10-Q.

Although Vanguard believes that the assumptions underlying the
forward-looking statements contained in this press release are reasonable,
any of these assumptions could prove to be inaccurate, and, therefore,
there can be no assurance that the forward-looking statements included in
this press release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included herein,
you should not regard the inclusion of such information as a representation
by Vanguard that its objectives and plans anticipated by the
forward-looking statements will occur or be achieved, or if any of them do,
what impact they will have on Vanguard’s results of operations and
financial condition. Vanguard undertakes no obligation to publicly release
any revisions to any forward-looking statements contained herein to reflect
events and circumstances occurring after the date hereof or to reflect the
occurrence of unanticipated events.

                          VANGUARD HEALTH SYSTEMS
        Condensed Consolidated Statements of Operations (Unaudited)
                              (In millions)


                                              Quarter ended June 30,
                                        ----------------------------------
                                              2009
                                          (as adjusted)         2010
                                        ----------------  ----------------
Patient service revenues                $ 629.3     76.1% $ 646.7     75.3%
Premium revenues                          197.2     23.9    211.7     24.7
                                        -------  -------  -------  -------
   Total revenues                         826.5    100.0    858.4    100.0
Costs and expenses:
   Salaries and benefits (includes
    stock compensation of $1.0 and $0.7,
    respectively)                         314.9     38.1    333.6     38.9
   Health plan claims expense             154.9     18.7    165.9     19.3
   Supplies                               116.1     14.0    116.7     13.6
   Provision for doubtful accounts         55.3      6.7     39.5      4.6
   Purchased services                      41.5      5.0     44.5      5.2
   Non-income taxes                        12.6      1.5     14.1      1.6
   Rents and leases                        10.8      1.3     11.0      1.3
   Other operating expenses                46.9      5.7     50.9      5.9
   Depreciation and amortization           34.2      4.1     37.7      4.4
   Interest, net                           27.0      3.3     30.8      3.6
   Debt extinguishment costs                  -        -      0.3        -
   Impairment loss                          6.2      0.8        -        -
   Other                                    0.7      0.1      5.6      0.7
                                        -------  -------  -------  -------
      Total costs and expenses            821.1     99.3    850.6     99.1
                                        -------  -------  -------  -------
Income from continuing operations
 before income taxes                        5.4      0.7      7.8      0.9
Income tax expense                         (3.3)    (0.4)    (4.4)    (0.5)
                                        -------  -------  -------  -------
Income from continuing operations           2.1      0.3      3.4      0.4
Income from discontinued operations,
 net of taxes                               0.6      0.1      0.2        -
                                        -------  -------  -------  -------
Net income                                  2.7      0.3      3.6      0.4
Less: Net income attributable to
 non-controlling interests                 (0.9)    (0.1)    (0.8)    (0.1)
                                        -------  -------  -------  -------
Net income attributable to Vanguard
 Health Systems, Inc. stockholders      $   1.8      0.2% $   2.8      0.3%
                                        =======  =======  =======  =======




                      VANGUARD HEALTH SYSTEMS, INC.
        Condensed Consolidated Statements of Operations (Unaudited)
                              (In millions)


                                            Year ended June 30,
                                ------------------------------------------
                                        2009                  2010
                                --------------------  --------------------
Patient service revenues        $ 2,507.4       78.7% $ 2,537.2      75.1%
Premium revenues                    678.0       21.3      839.7      24.9
                                ---------  ---------  ---------  --------
   Total revenues                 3,185.4      100.0    3,376.9     100.0
Costs and expenses:
   Salaries and benefits
    (includes stock
    compensation
    of $4.4 and $4.2,
    respectively)                 1,233.8       38.7    1,296.2      38.4
   Health plan claims expense       525.6       16.5      665.8      19.7
   Supplies                         455.5       14.3      456.1      13.5
   Provision for doubtful
    accounts                        210.3        6.6      152.5       4.5
   Purchased services               163.8        5.1      179.5       5.3
   Non-income taxes                  52.2        1.6       52.9       1.6
   Rents and leases                  42.6        1.3       43.8       1.3
   Other operating expenses         203.3        6.4      207.7       6.2
   Depreciation and
    amortization                    128.9        4.0      139.6       4.1
   Interest, net                    111.6        3.5      115.5       3.4
   Debt extinguishment costs            -          -       73.5       2.2
   Impairment loss                    6.2        0.2       43.1       1.3
   Other                              2.7        0.1        9.1       0.3
                                ---------  ---------  ---------  --------
      Total costs and expenses    3,136.5       98.5    3,435.3     101.7
                                ---------  ---------  ---------  --------
Income (loss) from continuing
 operations before income taxes      48.9        1.5      (58.4)     (1.7)
Income tax benefit (expense)        (16.8)      (0.5)      13.8       0.4
                                ---------  ---------  ---------  --------
Income (loss) from continuing
 operations                          32.1        1.0      (44.6)     (1.3)
Loss from discontinued
 operations, net of taxes            (0.3)      (0.0)      (1.7)     (0.1)
                                ---------  ---------  ---------  --------
Net income (loss)                    31.8        1.0      (46.3)     (1.4)
Less: Net income attributable
 to non-controlling interests        (3.2)      (0.1)      (2.9)     (0.1)
                                ---------  ---------  ---------  --------
Net income (loss) attributable
 to Vanguard Health Systems, Inc.
 stockholders                   $    28.6        0.9% $   (49.2)     (1.5)%
                                =========  =========  =========  ========




                      VANGUARD HEALTH SYSTEMS, INC.
              Supplemental Financial Information (Unaudited)
  Reconciliation of Adjusted EBITDA to Net Income (Loss) Attributable to
                Vanguard Health Systems, Inc. Stockholders
                              (In millions)


                                          Quarter Ended      Year Ended
                                             June 30,          June 30,
                                        ----------------  ----------------
                                          2009     2010     2009     2010
                                        -------  -------  -------  -------
Net income (loss) attributable to
 Vanguard Health Systems, Inc.
 stockholders                           $   1.8  $   2.8  $  28.6  $ (49.2)
Interest, net                              27.0     30.8    111.6    115.5
Income tax expense (benefit)                3.3      4.4     16.8    (13.8)
Depreciation and amortization              34.2     37.7    128.9    139.6
Non-controlling interests                   0.9      0.8      3.2      2.9
Loss (gain) on disposal of assets          (0.2)     1.4     (2.3)     1.8
Equity method income                       (0.4)    (0.1)    (0.8)    (0.9)
Stock compensation                          1.0      0.7      4.4      4.2
Monitoring fees and expenses                1.3      1.2      5.2      5.1
Realized loss on investments                  -        -      0.6        -
Impairment loss                             6.2        -      6.2     43.1
Acquisition related expenses                  -      3.1        -      3.1
Debt extinguishment costs                     -      0.3        -     73.5
Discontinued operations, net of taxes      (0.6)    (0.2)     0.3      1.7
                                        -------  -------  -------  -------
    Adjusted EBITDA (1)                 $  74.5  $  82.9  $ 302.7  $ 326.6
                                        =======  =======  =======  =======


(1) Adjusted EBITDA is defined as income before interest expense (net of
    interest income), income taxes, depreciation and amortization,
    non-controlling interests, gain or loss on disposal of assets, equity
    method income, stock compensation, monitoring fees and expenses,
    realized holding loss on investments, acquisition related expenses,
    debt extinguishment costs, impairment loss and discontinued operations,
    net of taxes. Adjusted EBITDA is not intended as a substitute for net
    income (loss) attributable to Vanguard Health Systems, Inc.
    stockholders, operating cash flows or other cash flow data determined
    in accordance with accounting principles generally accepted in the
    United States. Due to varying methods of calculation, Adjusted EBITDA
    as presented may not be comparable to similarly titled measures of
    other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                        Consolidated Balance Sheets
                              (In millions)


                                                      June 30,   June 30,
ASSETS                                                  2009       2010
                                                      ---------  ---------
Current assets:
  Cash and cash equivalents                           $   308.2  $   257.6
  Restricted cash                                           1.9        2.3
  Accounts receivable, net of allowance for doubtful
   accounts of approximately $121.5 and $75.6 at
   June 30, 2009 and June 30, 2010, respectively          275.3      270.4
  Inventories                                              48.3       49.6
  Deferred tax assets                                      29.6       21.9
  Prepaid expenses and other current assets                68.4      119.2
                                                      ---------  ---------
    Total current assets                                  731.7      721.0
Property, plant and equipment, net of accumulated
 depreciation                                           1,174.1    1,203.8
Goodwill                                                  692.1      649.1
Intangible assets, net of accumulated amortization         54.6       66.0
Deferred tax assets, noncurrent                            38.0       50.0
Investments in auction rate securities                     21.6       19.8
Other assets                                               19.0       19.9
                                                      ---------  ---------
    Total assets                                      $ 2,731.1  $ 2,729.6
                                                      =========  =========

LIABILITIES AND  EQUITY
Current liabilities:
  Accounts payable                                    $   127.9  $   194.8
  Accrued salaries and benefits                           133.9      144.9
  Accrued health plan claims and settlements              117.6      149.8
  Accrued interest                                         13.2       41.4
  Other accrued expenses and current liabilities           79.5       76.9
  Current maturities of long-term debt                      8.0        8.2
                                                      ---------  ---------
    Total current liabilities                             480.1      616.0
Professional and general liability and workers
 compensation reserves                                     76.7       83.6
Other liabilities                                          34.9       31.6
Long-term debt, less current maturities                 1,543.6    1,743.8
Commitments and contingencies
Equity:
  Vanguard Health Systems, Inc. stockholders' equity:
   Common stock                                               -          -
   Additional paid-in capital                             651.3      354.9
   Accumulated other comprehensive loss                    (6.8)      (2.5)
   Retained deficit                                       (56.7)    (105.9)
                                                      ---------  ---------
    Total Vanguard Health Systems, Inc. stockholders'
     equity                                               587.8      246.5
  Non-controlling interests                                 8.0        8.1
                                                      ---------  ---------
    Total equity                                          595.8      254.6
                                                      ---------  ---------
    Total liabilities and equity                      $ 2,731.1  $ 2,729.6
                                                      =========  =========




                         VANGUARD HEALTH SYSTEMS, INC.
                     Consolidated Statements of Cash Flows
                                 (In millions)


                                                            Year Ended
                                                             June 30,
                                                        ------------------
                                                          2009      2010
                                                        --------  --------
Operating activities:

Net income (loss)                                       $   31.8  $  (46.3)
Adjustments to reconcile net income (loss) to net cash
 provided by operating activities:
  Loss from discontinued operations                          0.3       1.7
  Depreciation and amortization                            128.9     139.6
  Provision for doubtful accounts                          210.3     152.5
  Amortization of loan costs and accretion of principal
   on notes                                                 27.2      11.7
  Loss (gain) on disposal of assets                         (2.3)      1.8
  Stock compensation                                         4.4       4.2
  Deferred income taxes                                      6.4      (8.5)
  Impairment loss                                            6.2      43.1
  Realized holding loss on investments                       0.6         -
  Acquisition related expenses                                 -       3.1
  Debt extinguishment costs                                    -      73.5
  Changes in operating assets and liabilities:
   Accounts receivable                                    (185.6)   (148.3)
   Inventories                                               1.0      (1.3)
   Prepaid expenses and other current assets               (12.7)    (80.5)
   Accounts payable                                        (27.5)     67.1
   Accrued expenses and other liabilities                  122.7     102.8
                                                        --------  --------
Net cash provided by operating activities - continuing
 operations                                                311.7     316.2
Net cash provided by (used in) operating activities -
 discontinued operations                                     1.4      (1.0)
                                                        --------  --------
Net cash provided by operating activities                  313.1     315.2

Investing activities:
Acquisitions and related expenses                           (4.4)     (4.6)
Capital expenditures                                      (132.0)   (155.9)
Proceeds from asset dispositions                             4.9       2.0
Sales of auction rate securities                               -       1.8
Other                                                       (2.0)      0.3
                                                        --------  --------
Net cash used in investing activities - continuing
 operations                                               (133.5)   (156.4)
Net cash used in investing activities - discontinued
 operations                                                 (0.1)     (0.1)
                                                        --------  --------
Net cash used in investing activities                     (133.6)   (156.5)

Financing activities:
Payments of long-term debt                                  (7.8) (1,557.4)
Proceeds from debt borrowings                                  -   1,751.3
Payments of refinancing costs and fees                         -     (93.6)
Repurchases of stock and stock options                      (0.2)   (300.6)
Payments related to derivative instrument with
 financing element                                             -      (6.2)
Distributions paid to non-controlling interests and
 other                                                      (4.9)     (2.8)
                                                        --------  --------
Net cash used in financing activities                      (12.9)   (209.3)
                                                        --------  --------
Net increase (decrease) in cash and cash equivalents       166.6     (50.6)
Cash and cash equivalents, beginning of year               141.6     308.2
                                                        --------  --------
Cash and cash equivalents, end of year                  $  308.2  $  257.6
                                                        ========  ========




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                                Three months ended June 30, 2009
                      ----------------------------------------------------
                       Acute
                       Care     % of     Health   % of    Elimin-  Consol-
                     Services Revenues   Plans  Revenues  ations   idated
                      -------  ------   -------- -------  -------  -------
Patient service
 revenues(1)          $ 638.3   100.0%  $      -       -% $  (9.0) $ 629.3
Premium revenues            -       -      197.2   100.0        -    197.2
                      -------  ------   -------- -------  -------  -------
   Total revenues       638.3   100.0      197.2   100.0     (9.0)   826.5

Salaries and benefits
 (excludes stock
 compensation)          306.0    47.9        7.9     4.0        -    313.9
Health plan claims
 expense                    -       -      163.9    83.1     (9.0)   154.9
Supplies                116.0    18.2        0.1     0.1        -    116.1
Provision for
 doubtful
 accounts                55.3     8.7          -       -        -     55.3
Other operating
 expenses               102.2    16.0        9.6     4.9        -    111.8
                      -------  ------   -------- -------  -------  -------
   Total operating
    expenses            579.5    90.8      181.5    92.0     (9.0)   752.0
                      -------  ------   -------- -------  -------  -------
   Segment EBITDA(2)     58.8     9.2       15.7     8.0        -     74.5
Less:
 Interest, net           26.8     4.2        0.2     0.1        -     27.0
 Depreciation and
  amortization           33.1     5.2        1.1     0.6        -     34.2
 Equity method income    (0.4)   (0.1)         -       -        -     (0.4)
 Stock compensation       1.0     0.2          -       -        -      1.0
 Gain on disposal of
  assets                 (0.2)   (0.0)         -       -        -     (0.2)
 Monitoring fees and
  expenses                1.3     0.2          -       -        -      1.3
Impairment loss           6.2     1.0          -       -        -      6.2
                      -------  ------   -------- -------  -------  -------
 Income (loss) from
  continuing operations
  before income taxes $  (9.0)   (1.4)% $   14.4     7.3% $     -  $   5.4
                      =======  ======   ======== =======  =======  =======


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the corresponding
    medical claims expenses incurred by the health plans for those
    services.

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of non-cash
    depreciation of tangible assets and amortization of intangible assets,
    much of which results from acquisitions accounted for under the
    purchase method of accounting. Segment EBITDA also eliminates the
    effects of changes in interest rates which management believes relate
    to general trends in global capital markets, but are not necessarily
    indicative of the operating performance of Vanguard's segments.
    Management believes that Segment EBITDA provides useful information
    about the financial performance of Vanguard's segments to investors,
    lenders, financial analysts and rating agencies. Additionally,
    management believes that investors and lenders view Segment EBITDA as
    an important factor in making investment decisions and assessing the
    value of Vanguard. Segment EBITDA is not a substitute for net income
    (loss), operating cash flows or other cash flow statement data
    determined in accordance with accounting principles generally accepted
    in the United States. Segment EBITDA, as presented, may not be
    comparable to similar  measures of other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                               Three months ended June 30, 2010
                  --------------------------------------------------------
                   Acute
                    Care      % of    Health     % of   Elimina-  Consoli-
                  Services  Revenues   Plans   Revenues  tions     dated
                  --------  -------   -------  -------  --------  --------
Patient service
 revenues(1)      $  657.8    100.0%  $     -        -% $  (11.1) $  646.7
Premium revenues         -        -     211.7    100.0         -     211.7
                  --------  -------   -------  -------  --------  --------
 Total revenues      657.8    100.0     211.7    100.0     (11.1)    858.4

Salaries and
 benefits
 (excludes stock
 compensation)       324.0     49.3       8.9      4.2         -     332.9
Health plan
 claims expense          -        -     177.0     83.6     (11.1)    165.9
Supplies             116.7     17.7         -        -         -     116.7
Provision for
 doubtful
 accounts             39.5      6.0         -        -         -      39.5
Other operating
 expenses            110.8     16.8       9.7      4.6         -     120.5
                  --------  -------   -------  -------  --------  --------
  Total operating
   expenses          591.0     89.8     195.6     92.4     (11.1)    775.5
                  --------  -------   -------  -------  --------  --------
  Segment EBITDA(2)   66.8     10.2      16.1      7.6         -      82.9
Less:
 Interest, net        31.2      4.7      (0.4)    (0.2)        -      30.8
 Depreciation and
  amortization        36.6      5.6       1.1      0.5         -      37.7
 Equity method
  income              (0.1)    (0.0)        -        -         -      (0.1)
 Stock compensation    0.7      0.1         -        -         -       0.7
 Loss on disposal
  of assets            1.4      0.2         -        -         -       1.4
 Monitoring fees
  and expenses         1.2      0.2         -        -         -       1.2
 Acquisition
  related expenses     3.1      0.5         -        -         -       3.1
 Debt
  extinguishment
  costs                0.3        -         -        -         -       0.3
                  --------  -------   -------  -------  --------  --------
  Income (loss)
   from continuing
   operations
   before income
   taxes          $   (7.6)    (1.2)% $  15.4      7.3% $      -  $    7.8
                  ========  =======   =======  =======  ========  ========


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the
    corresponding medical claims expenses incurred by the health plans for
    those services.

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of
    non-cash depreciation of tangible assets and amortization of
    intangible assets, much of which results from acquisitions accounted
    for under the purchase method of accounting. Segment EBITDA also
    eliminates the effects of changes in interest rates which management
    believes relate to general trends in global capital markets, but are
    not necessarily indicative of the operating performance of Vanguard's
    segments. Management believes that Segment EBITDA provides useful
    information about the financial performance of Vanguard's segments to
    investors, lenders, financial analysts and rating agencies.
    Additionally, management believes that investors and lenders view
    Segment EBITDA as an important factor in making investment decisions
    and assessing the value of Vanguard. Segment EBITDA is not a
    substitute for net income (loss), operating cash flows or other cash
    flow statement data determined in accordance with accounting
    principles generally accepted in the United States. Segment EBITDA,
    as presented, may not be comparable to similar
    measures of other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                                  Year ended June 30, 2009
                  --------------------------------------------------------
                    Acute
                    Care      % of    Health    % of    Elimina-  Consoli-
                  Services  Revenues  Plans   Revenues    tions     dated
                  --------  --------  ------  --------  --------  --------
Patient service
 revenues(1)      $2,541.4     100.0% $    -         -% $  (34.0) $2,507.4
Premium revenues         -         -   678.0     100.0         -     678.0
                  --------  --------  ------  --------  --------  --------
  Total revenues   2,541.4     100.0   678.0     100.0     (34.0)  3,185.4

Salaries and
 benefits
 (excludes stock
 compensation)     1,198.8      47.2    30.6       4.5         -   1,229.4
Health plan
 claims expense          -         -   559.6      82.5     (34.0)    525.6
Supplies             455.2      17.9     0.3         -         -     455.5
Provision for
 doubtful
 accounts            210.3       8.3       -         -         -     210.3
Other operating
 expenses            425.5      16.7    36.4       5.4         -     461.9
                  --------  --------  ------  --------  --------  --------
  Total operating
   expenses        2,289.8      90.1   626.9      92.5     (34.0)  2,882.7
                  --------  --------  ------  --------  --------  --------
  Segment EBITDA(2)  251.6       9.9    51.1       7.5         -     302.7
Less:
 Interest, net       112.2       4.4    (0.6)     (0.1)        -     111.6
 Depreciation and
  amortization       124.8       4.9     4.1       0.6         -     128.9
 Equity method
  income              (0.8)     (0.0)      -         -         -      (0.8)
 Stock
  compensation         4.4       0.2       -         -         -       4.4
 Gain on disposal
  of assets           (2.3)     (0.1)      -         -         -      (2.3)
 Monitoring fees
  and expenses         5.2       0.2       -         -         -       5.2
 Realized holding
  loss on
  investments          0.6         -       -         -         -       0.6
 Impairment loss       6.2       0.2       -         -         -       6.2
                  --------  --------  ------  --------  --------  --------
  Income from
   continuing
   operations
   before income
   taxes          $    1.3       0.1% $ 47.6       7.0% $      -  $   48.9
                  ========  ========  ======  ========  ========  ========


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the
    corresponding medical claims expenses incurred by the health plans for
    those services

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of
    non-cash depreciation of tangible assets and amortization of
    intangible assets, much of which results from acquisitions accounted
    for under the purchase method of accounting. Segment EBITDA also
    eliminates the effects of changes in interest rates which management
    believes relate to general trends in global capital markets, but are
    not necessarily indicative of the operating performance of Vanguard's
    segments. Management believes that Segment EBITDA provides useful
    information about the financial performance of Vanguard's segments to
    investors, lenders, financial analysts and rating agencies.
    Additionally, management believes that investors and lenders view
    Segment EBITDA as an important factor in making investment decisions
    and assessing the value of Vanguard. Segment EBITDA is not a
    substitute for net income (loss), operating cash flows or other cash
    flow statement data determined in accordance with accounting
    principles generally accepted in the United States. Segment EBITDA,
    as presented, may not be comparable to similar measures of other
    companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                                  Year ended June 30, 2010
                  --------------------------------------------------------
                    Acute
                    Care      % of    Health     % of   Elimina-  Consoli-
                  Services  Revenues   Plans   Revenues  tions     dated
                  --------  -------   -------  -------  --------  --------
Patient service
 revenues(1)      $2,580.0    100.0 % $     -        -% $  (42.8) $2,537.2
Premium revenues         -        -     839.7    100.0         -     839.7
                  --------  -------   -------  -------  --------  --------
  Total revenues   2,580.0    100.0     839.7    100.0     (42.8)  3,376.9

Salaries and
 benefits
 (excludes stock
 compensation)     1,257.9     48.8      34.1      4.1         -   1,292.0
Health plan
 claims expense          -        -     708.6     84.4     (42.8)    665.8
Supplies             456.0     17.7       0.1        -         -     456.1
Provision for
 doubtful
 accounts            152.5      5.9         -        -         -     152.5
Other operating
 expenses            447.0     17.3      36.9      4.4         -     483.9
                  --------  -------   -------  -------  --------  --------
  Total operating
   expenses        2,313.4     89.7     779.7     92.9     (42.8)  3,050.3
                  --------  -------   -------  -------  --------  --------
  Segment EBITDA(2)  266.6     10.3      60.0      7.1         -     326.6
Less:
 Interest, net       116.5      4.5      (1.0)    (0.1)        -     115.5
 Depreciation and
  amortization       135.2      5.2       4.4      0.5         -     139.6
 Equity method
  income              (0.9)    (0.0)        -        -         -      (0.9)
 Stock
  compensation         4.2      0.2         -        -         -       4.2
 Loss on disposal
  of assets            1.8      0.1         -        -         -       1.8
 Monitoring fees
  and expenses         5.1      0.2         -        -         -       5.1
 Acquisition
  related expenses     3.1      0.1         -        -         -       3.1
 Debt
  extinguishment
  costs               73.5      2.8         -        -         -      73.5
 Impairment loss      43.1      1.7         -        -         -      43.1
                  --------  -------   -------  -------  --------  --------
  Income (loss)
   from
   continuing
   operations
   before income
   taxes          $ (115.0)    (4.5)% $  56.6      6.7% $      -  $  (58.4)
                  ========  =======   =======  =======  ========  ========


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the corresponding
    medical claims expenses incurred by the health plans for  those
services.

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of non-cash
    depreciation of tangible assets and amortization of intangible assets,
    much of which results from acquisitions accounted for under the
    purchase method of accounting. Segment EBITDA also eliminates the
    effects of changes in interest rates which management believes relate
    to general trends in global capital markets, but are not necessarily
    indicative of the operating performance of Vanguard's segments.
    Management believes that Segment EBITDA provides useful information
    about the financial performance of Vanguard's segments to investors,
    lenders, financial analysts and rating agencies. Additionally,
    management believes that investors and lenders view Segment EBITDA as
    an important factor in making investment decisions and assessing the
    value of Vanguard. Segment EBITDA is not a substitute for net income
    (loss), operating cash flows or other cash flow statement data
    determined in accordance with accounting principles generally accepted
    in the United States. Segment EBITDA, as presented, may not be
    comparable to similar measures of other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Selected Operating Statistics
                                (Unaudited)

                                                Three months ended
                                                     June 30,
                                                 ----------------
                                                   2009     2010   % Change
                                                 -------  -------  -------
Number of hospitals at end of period                  15       15
Licensed beds at end of period                     4,135    4,135
Discharges                                        41,400   42,159      1.8%
Adjusted discharges                               73,210   75,620      3.3
Adjusted discharges - hospitals                   69,258   71,657      3.5
Average length of stay                              4.18     4.09     (2.2)
Patient days                                     173,022  172,388     (0.4)
Adjusted patient days                            305,966  309,209      1.1
Adjusted patient days - hospitals                289,447  293,003      1.2
Patient revenue per adjusted discharge           $ 8,422  $ 8,407     (0.2)
Patient revenue per adjusted discharge -
 hospitals                                       $ 8,850  $ 8,560     (3.3)
Inpatient surgeries                                9,530    9,244     (3.0)
Outpatient surgeries                              19,521   19,084     (2.2)
Emergency room visits                            158,936  160,523      1.0%

Charity care and uninsured discounts as a
 percent of acute care segment revenues
 (prior to these discounts)(1)                       4.9%    10.8%

Provision for doubtful accounts as a percent of
 acute care services segment revenues (prior to
 charity and uninsured discounts)(1)                 8.2%     5.4%

Net patient revenue payer mix:
   Medicare                                         24.8%    25.0%
   Medicaid                                          7.7      7.6
   Managed Medicare                                 14.7     14.7
   Managed Medicaid                                  9.1      9.3
   Managed care                                     34.0     35.2
   Commercial                                        0.9      1.0
   Self pay                                          8.8      7.2
                                                 -------  -------
      Total                                        100.0%   100.0%
                                                 =======  =======

Discharges by payer:
   Medicare                                         26.7%    27.8%
   Medicaid(1)                                       9.7      9.3
   Managed Medicare                                 16.5     16.3
   Managed Medicaid                                 14.3     15.2
   Managed care                                     28.3     26.4
   Commercial                                        0.4      0.4
   Self pay(1)                                       4.1      4.6
                                                 -------  -------
      Total                                        100.0%   100.0%
                                                 =======  =======


(1) See Supplemental Operating Measures Adjusted For Comparative Analysis
    for the impact to the ratio of charity and uninsured discounts as a
    percent of acute care services segment revenues, the ratio of
    provision for doubtful accounts as a percent of acute care services
    segment revenues and Medicaid and self pay discharges of the change
    in our Medicaid pending policy during the three months ended June
    30, 2010.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Selected Operating Statistics
                          (Unaudited) (continued)


                                            Year ended June 30,
                                           --------------------
                                             2009       2010     % Change
                                           ---------  ---------  ---------
Number of hospitals at end of period              15         15
Licensed beds at end of period                 4,135      4,135
Discharges                                   167,880    168,370        0.3%
Adjusted discharges                          288,807    295,702        2.4
Adjusted discharges - hospitals              274,767    280,437        2.1
Average length of stay                          4.23       4.17       (1.4)
Patient days                                 709,952    701,265       (1.2)
Adjusted patient days                      1,221,345  1,231,604        0.8
Adjusted patient days - hospitals          1,161,967  1,168,027        0.5
Patient revenue per adjusted discharge     $   8,503  $   8,408       (1.1)
Patient revenue per adjusted discharge -
 hospitals                                 $   8,623  $   8,516       (1.2)
Inpatient surgeries                           37,970     37,320       (1.7)
Outpatient surgeries                          76,378     75,969       (0.5)
Emergency room visits                        605,729    626,237        3.4%

Charity care and uninsured discounts as a
 percent of acute care services segment
 revenues (prior to these discounts)             3.9%      10.5%

Provision for doubtful accounts as a
 percent of acute care services segment
 revenues (prior to charity and uninsured
 discounts)(1)                                   8.0%       5.3%

Net patient revenue payer mix:
   Medicare                                     25.3%      25.5%
   Medicaid                                      7.9        7.4
   Managed Medicare                             14.1       14.8
   Managed Medicaid                              8.8        9.5
   Managed care                                 34.7       34.9
   Commercial                                    0.9        1.1
   Self pay                                      8.3        6.8
                                           ---------  ---------
      Total                                    100.0%     100.0%
                                           =========  =========

Discharges by payer:
   Medicare                                     27.1%      27.5%
   Medicaid (1)                                 10.2        8.8
   Managed Medicare                             16.0       16.3
   Managed Medicaid                             13.8       15.3
   Managed care                                 29.2       26.8
   Commercial                                    0.3        0.4
   Self pay (1)                                  3.4        4.9
                                           ---------  ---------
      Total                                    100.0%     100.0%
                                           =========  =========

(1) See Supplemental Operating Measures Adjusted For Comparative Analysis
    for the impact to the ratio of charity and uninsured discounts as a
    percent of acute care services segment revenues, the ratio of provision
    for doubtful accounts as a percent of acute care services segment
    revenues and Medicaid and self pay discharges of the change in our
    Medicaid pending policy during the year ended June 30, 2010.




                      VANGUARD HEALTH SYSTEMS, INC.
    Supplemental Operating Measures Adjusted for Comparative Analysis
                 For the three months ended June 30, 2010
          (dollars in millions, except for statistical measures)
                                (Unaudited)


                         Impact of Policy           % of Segment Revenues
                             Changes                ----------------------
                 GAAP-   ----------------  Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted  GAAP    adjusted(4)
                 amounts discounts pending amounts   basis  --------------
                   (1)      (2)      (3)     (4)     2010    2009    2010
                 ------- --------  ------  -------  ------  ------  ------
Acute care
 services
 segment:
 Total
  revenues(5)    $ 657.8 $   33.5  $ (4.7) $ 686.6   100.0%  100.0%  100.0%
 Salaries and
  benefits(8)    $ 324.7 $      -  $    -  $ 324.7    49.4    47.6    47.3
 Supplies        $ 116.7 $      -  $    -  $ 116.7    17.7    18.0    17.0
 Provision for
  doubtful
  accounts       $  39.5 $   33.5  $ (3.6) $  69.4     6.0     9.6    10.1
 Other operating
  expenses       $ 110.8 $      -  $    -  $ 110.8    16.8    15.8    16.1
 Total operating
  expenses       $ 591.7 $   33.5  $ (3.6) $ 621.6    90.0%   91.0 %  90.5%


                                                    % of Segment Revenues
                                                     Prior to Charity and
                         Impact of Policy            Uninsured Discounts
                             Changes                ----------------------
                 GAAP-   ----------------  Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted  GAAP    adjusted(4)
                 amounts discounts pending amounts   basis  --------------
                   (1)      (2)      (3)     (4)     2010     2009   2010
                 ------- --------  ------  -------  ------  ------  ------
Uncompensated
 care(6)         $ 117.8 $  (21.2) $ (3.6) $  93.0    16.0%   12.4%   13.1%
Total revenues,
 prior
 to charity(7)   $ 681.3 $   33.5  $ (4.7) $ 710.1


                  2010                           2010
              Statistical   2010      2010   Statistical   2009    Current
Vanguard        Measure   Uninsured Medicaid   Measure   Measure    year
consolidated:      as     discounts  pending      as        as    change as
               reported      (2)       (3)    adjusted  adjusted  adjusted
                -------   --------   ------    -------   -------   ------
Patient revenue
 per total
 adjusted
 discharge      $ 8,407   $    443   $  (62)   $ 8,788   $ 8,516      3.2%
Self-pay
 discharges       1,942          -     (600)     1,342     1,526    (12.1)%
Medicaid
 discharges       3,910          -      600      4,510     4,197      7.5%




                      VANGUARD HEALTH SYSTEMS, INC.
    Supplemental Operating Measures Adjusted for Comparative Analysis
                     For the year ended June 30, 2010
          (dollars in millions, except for statistical measures)
                                (Unaudited)


                         Impact of Policy           % of Segment Revenues
                             Changes               -----------------------
                 GAAP-   ---------------   Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted GAAP    adjusted(4)
                 amounts discounts pending amounts  basis  ---------------
                   (1)      (2)      (3)     (4)    2010    2009     2010
                 -------- ------  ------  -------- ------  -----   -------
Acute care
 services
 segment:
 Total
  revenues(5)    $2,580.0 $128.7  $(22.9) $2,685.8  100.0% 100.0%    100.0%
 Salaries and
  benefits(8)    $1,262.1 $    -  $    -  $1,262.1   48.9   47.2      47.0
 Supplies        $  456.0 $    -  $    -  $  456.0   17.7   17.9      17.0
 Provision for
  doubtful
  accounts       $  152.5 $128.7  $(22.3) $  258.9    5.9    8.5       9.6
 Other operating
  expenses       $  447.0 $    -  $    -  $  447.0   17.3   16.7      16.6
 Total operating
  expenses       $2,317.6 $128.7  $(22.3) $2,424.0   89.8%  90.3%     90.3%


                                                    % of Segment Revenues
                                                     Prior to Charity and
                         Impact of Policy            Uninsured Discounts
                             Changes                ----------------------
                 GAAP-   ----------------  Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted  GAAP    adjusted(4)
                 amounts   dis-   pending  amounts  basis  ---------------
                   (1)   counts(2)  (3)     (4)      2010   2009     2010
                 -------- ------  ------  --------  -----  -----    ------
Uncompensated
 care(6)         $  455.9 $(87.0) $(22.3) $  346.6   15.8%  11.6%     12.5%

Total revenues,
 prior to
 charity(7)      $2,667.7 $128.7  $(22.9) $2,773.5


                  2010                           2010
              Statistical   2010      2010   Statistical   2009    Current
Vanguard        Measure   Uninsured Medicaid   Measure   Measure    year
consolidated:      as     discounts  pending      as        as    change as
               reported      (2)       (3)    adjusted  adjusted  adjusted
                -------   --------   ------    -------   -------   ------
Patient revenue
 per total
 adjusted
 discharge      $ 8,408   $    435   $  (79)   $ 8,764   $ 8,527      2.8%
Self-pay
 discharges       8,168          -   (2,717)     5,451     5,483     (0.6)%
Medicaid
 discharges      14,867          -    2,717     17,584    17,235      2.0%


(1) Amounts reflected in or components of amounts reflected in the
    segment information tables included in this release. These amounts
    are based upon revenues or expenses determined in accordance with
    accounting principles generally accepted in the United States.

(2) Includes the impact of the uninsured discount policy implemented
    for Vanguard's Illinois hospitals effective April 1, 2009 and for
    it Phoenix and San Antonio hospitals effective July 1, 2009. Under
    this policy, Vanguard applies an uninsured discount (calculated as
    a standard percentage of gross revenues) at the time of patient
    billing and includes the discount as a reduction of revenues. This
    uninsured discount program applies to patients receiving hospital
    services who have no insurance coverage and do not otherwise meet
    Vanguard's charity care guidelines. Vanguard recorded a total of
    $11.7 million and $54.7 million of uninsured discounts relates to
    its acute care services segment during the three months ended June
    30, 2009 and 2010, respectively. Of these amounts $7.6 million and
    $33.5 million for the three months ended June 30, 2009 and 2010,
    respectively, related to non-Medicaid pending accounts that reduced
    revenues as a result of implementing this policy. Vanguard recorded
    a total of $11.7 million and $215.7 million of uninsured discounts
    related to its acute care services segment during the years ended
    June 30, 2009 and 2010, respectively. Of these amounts, $7.6 million
    and $128.7 million for the years ended June 30, 2009 and 2010,
    respectively, related to non-Medicaid pending accounts that reduced
    revenues as a result of implementing this policy.

(3) Includes the impact of Vanguard's policy change for accounts pending
    Medicaid qualification. Prior to the implementation of its new
    uninsured discount policy, Vanguard classified accounts pending
    Medicaid qualification as Medicaid revenues (and Medicaid discharges)
    and recorded a contractual discount for these accounts based upon
    the average Medicaid reimbursement rate for each specific state until
    qualification was confirmed. Vanguard implemented a new Medicaid
    pending policy for all of its hospitals whereby Medicaid pending
    accounts are classified as self-pay revenues (and self-pay discharges)
    with an uninsured discount applied. The balance of these accounts is
    subject to Vanguard's allowance for doubtful accounts policy. For
    those accounts that subsequently qualify for Medicaid coverage, the
    uninsured discount is reversed and the account is reclassified to
    Medicaid revenues (and Medicaid discharges) with the appropriate
    contractual discount applied. The difference between the
    state-specific Medicaid contractual discounts under the previous
    policy and the uninsured discount percentage applied to Medicaid
    pending accounts under the new policy increased total revenues by
    $0.7 million, $4.7 million, $0.7 million and $22.9 million for the
    three months ended June 30, 2009 and 2010 and the years ended June
    30, 2009 and 2010, respectively. The provision for doubtful accounts
    recorded for Medicaid pending accounts, after the uninsured discounts
    were applied, were $1.0 million, $3.6 million, $1.0 million and $22.3
    million for the three months ended June 30, 2009 and 2010 and the
    years ended June 30, 2009 and 2010, respectively.

(4) Revenues, certain expenses and those expenses as a percentage of
    revenues for the acute care services segment for the three months and
    year ended June 30, 2010 have been adjusted to allow for comparative
    measurement on a basis consistent with the three months and year ended
    June 30, 2009 (before implementation of the majority of the uninsured
    discount policy or the change to the Medicaid pending policy).
    Management believes these non-GAAP measures will provide investors,
    analysts and general users of this financial information an effective
    means to compare the operating results of Vanguard's acute care
    services segment for the current year periods to those of the prior
    year periods. However, these non-GAAP operating measures are not
    meant to replace GAAP-basis revenues, expenses or expenses as a
    percentage of revenues as operating performance indicators for the
    acute care services segment.

(5) Total revenues for the acute care services segment represent revenues
    prior to the elimination in consolidation of revenues earned by
    Vanguard's hospitals for services provided to enrollees in Vanguard's
    owned health plans.

(6) Uncompensated care is defined as the sum of uninsured discounts,
    charity deductions and the provision for doubtful accounts.

(7) Represents total revenues for the acute care services segment plus
    charity deductions.

(8) Includes stock compensation.

MOUNTAINSIDE, NJ–(Marketwire – August 25, 2010) –  PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors. 

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (“XGen”), a Nevis Island limited liability company. For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

About Proteonomix, Inc.:

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. More specifically, the investment may never occur negating the agreement, product performance and/or side effects may necessitate termination of the joint venture, the implementation of the agreement may not succeed and inadequate or no business may develop causing the failure of the joint venture and there are inherent risks in foreign operations, particularly those in the Mideast. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Click here to see all recent news from this company

PHOENIX, AZ–(Marketwire – August 25, 2010) –  Remuda Ranch Programs for Eating and Anxiety Disorders reports in the past five years, self-injury, particularly cutting oneself, is becoming more prevalent among eating disorder patients. 

“Approximately 40 to 50 percent of our patients have either reported a history of self-injury or are presently engaging in these behaviors,” said Dena Cabrera, PsyD, psychologist and national speaker at Remuda Ranch. “This number seems to be consistent for the past five years. Studies have shown that adolescents engaging in self-injury behavior were more likely to have an eating disorder.”

Cutting may be increasing in our culture because young women today are struggling with identity issues and dealing with challenging problems. They feel they have to go to extremes to show others that they are suffering. Often, they are suffering from depression. In a visual culture, cutting may be a voice to get needs met. Self-injury may represent that struggle visually while physiologically and emotionally numbing the pain.

Based on studies and direct patient reports, Dr. Cabrera lists the following as additional reasons for self-injury:

• Stimulation: Escaping dissociative experience through an intentional gesture to feel one’s body, thereby using self-injury as a self-grounding technique.
• Emotional Release: Self-imposed when feeling guilt, shame, weakness, anger or punishment.
• Relaxation: A pleasure response to the warmth of the blood and to the physical sensation of pain.
• Distraction: Inducing dissociation or a trance-like state to avoid attending to an emotional trigger, issue, subject or suicidal thoughts.
• Social Attention: Obtaining self-affirmation by showing oneself and others one’s strength and achieving protection through the response of others.
• Alteration: Altering one’s body to make it unattractive to others through scarring.

At Remuda Ranch, Dialectical Behavior Therapy is used to teach patients skills to replace the self-harm behavior whether that behavior is an eating disorder, cutting, or both.

“We provide structure to the patient’s environment to motivate, reinforce and individualize appropriate skills needed for recovery,” adds Dr. Cabrera. “We also help remove negative behaviors as well as establish plans in case of relapse.”

“If someone you know is practicing self-injury it’s important to get help immediately,” said Dr. Cabrera. “Cutting is not like biting your nails, it can be very dangerous. Further, it perpetuates low self worth and esteem. It becomes a vicious cycle.”

About Remuda Ranch Programs for Eating and Anxiety Disorders
Remuda Ranch offers inpatient and residential programs for individuals of all faiths suffering from eating or anxiety disorders. Each patient is treated by a multi-disciplinary team including a psychiatric and a primary care provider, registered dietitian, master’s level therapist, psychologist and registered nurse. The professional staff equips each patient with the right tools to live a healthy, productive life. For more information, call
1-800-445-1900 or visit www.remudaranch.com.

Click here to see all recent news from this company

LEXINGTON, MA–(Marketwire – August 25, 2010) –  Imprivata^®, Inc., the company that simplifies and secures user access, today announced the formation of its Healthcare Advisory Board. This board draws upon real-world perspectives of industry leaders to address healthcare IT challenges and trends as the company develops innovative and practical solutions that solve the unique challenges facing the healthcare industry. Chaired by Barry P. Chaiken, MD, MPH, FHIMSS, chief medical officer of Imprivata, the Healthcare Advisory Board is comprised of Imprivata customers and industry experts, including:

• Michael Westcott, MD, CMIO, Alegent Health
• Denis Le Beuf, Chief Information Security Officer, Centre Hospitalier de l’Universite de Montreal
• Tarun Ghosh, CIO, Fremont-Rideout Health Group
• John Fernandez, CEO, Massachusetts Eye and Ear Infirmary
• Michael Krouse, Senior Vice President and CIO, OhioHealth
• Ted Lewis, President, Parkview Adventist Medical Center
• Deborah Peel, MD, Founder and Chair, Patient Privacy Rights

Through open sharing of experiences, dialogue about trends and regulatory influences and thoughtful debate, this new Healthcare Advisory Board is the latest example of Imprivata’s commitment to helping hospitals improve clinician workflow, enforce patient privacy and deploy transparent security.

“Today’s healthcare organizations face constant change, new regulatory mandates and a unique working environment that demands quick access to information but tight security on patient data,” said Dr. Michael Westcott, CMIO of Alegent Health, the largest healthcare system in Nebraska. The not-for-profit, faith based health care provider, which is 9,000 employees strong, has been an Imprivata customer since 2006. “One of the primary goals of the Healthcare Advisory Board is to share our experiences, study our similarities and differences, develop creative solutions to the challenges we face as an industry, and help Imprivata develop practical solutions that make a difference in hospitals around the world,” Dr. Westcott explained.

The Healthcare Advisory Board held its first meeting in Boston in June 2010 and will meet again in December. While topics for discussion at the first meeting were broad, there were clear commonalities among this varied group of healthcare organizations. Among the topics were:

• The impacts of the Healthcare Information Portability and Privacy (HIPAA) and Health Information Technology for Economic and Clinical Health (HITECH) Acts
• The role of access management in the implementation and “Meaningful Use” of EMRs
• Health information exchanges (HIEs) and the accompanying Beacon Grants (in ARRA)
• SSO and Strong Authentication enhancements for improved workflow
• Privacy and security
• Compliance demonstration, auditing and reporting
• Enterprise-wide business intelligence
• SaaS/cloud computing

“With the Healthcare Advisory Board, we have built a community of trusted, experienced and motivated members that are dedicated to triage industry priorities and provide fresh perspectives from C-level leaders,” said Barry P. Chaiken, MD, MPH, FHIMSS, chief medical officer of Imprivata. “I am very proud to be working with this diverse group of industry insiders and influencers to solve the problems of tomorrow — fast EMR access, patient privacy, security — today.”

Built upon a foundation of deep healthcare industry experience, Imprivata strives to make patient data easily accessible throughout clinical workflows, empowering physicians, nurses and other clinicians with fast EMR access, while enforcing stringent patient privacy policies through transparent security across healthcare information systems. Today Imprivatas’ Global Healthcare Division, has more than 550 healthcare customers and one million-plus healthcare users worldwide. 

“Imprivata long ago established a firm commitment to the healthcare industry, which has in turn fueled our rapid growth in recent years,” said Omar Hussain, president and CEO of Imprivata. “We have a history of not asking our customers what products they need, but rather spending time understanding what their problems and concerns are. It is in this mindset that we’re excited to tap into some of the healthcare industry’s brightest minds to spark vibrant discussion and help shape what solutions Imprivata brings to market over the long term.”

About Imprivata
Imprivata is the leading independent vendor focused on simplifying and securing user access. By strengthening user authentication, streamlining application access and simplifying compliance reporting across multiple computing environments, customers can align security with user workflows and realize substantial productivity gains while lowering IT costs.

Imprivata has received numerous product awards and top review ratings from leading industry publications and analysts. Headquartered in Lexington, Mass., Imprivata partners with over 200 resellers, and serves the access security needs of more than 1,000 customers around the world. For more information, please visit www.imprivata.com.

RSS Feed to Imprivata News: http://feeds.feedburner.com/ImprivataNews

Follow Imprivata on Twitter: https://twitter.com/Imprivata

id=”nav_links”>

DALLAS, TX–(Marketwire – August 25, 2010) –  Metiscan, Inc. (PINKSHEETS: MTIZ), the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services, today announces results for its second quarter ending June 30, 2010. During the three months ended June 30, 2010, revenues were up 47% and cost of revenues were reduced 25% compared to the three months ended June 30, 2009. Additionally, for the first half of 2010, the Company had positive income from operations of $184,464 and would have had positive net income of approximately $140,000, if not for a one-time write-off of uncollectable notes of approximately $350,000 in the first quarter of 2010.

Interested parties may access MTIZ’s recent 10-Q from the SEC website at www.SEC.gov.

During the three months ended June 30, 2010 the Company’s revenues were $514,862 as compared to $349,423 during the three months ended June 30, 2009. This increase of $165,439, or 47%, is primarily the result of the Company’s operation of Schuylkill Open MRI, Inc. and FirstView EHR, Inc.

The Company’s cost of revenues during the three months ended June 30, 2010 were $140,333 as compared to $181,066 during the three months ended June 30, 2009. Cost of revenues as a percentage of revenues were 27% during the three months ended June 30, 2010 as compared to 52% during the three months ended June 30, 2009. This decrease of $40,733 or 25% is a result of the increased revenues with the Company’s change in operational focus.

During the six months ended June 30, 2010 the Company’s revenues were $1,413,490 as compared to $1,219,379 during the six months ended June 30, 2009, an increase of $194,111, or 16%. Additionally, for the first half of 2010, the Company demonstrated positive income from operations of $184,464 and would have had positive net income of approximately $140,000, if not for a one-time write-off of uncollectable notes of approximately $350,000 in Q1 of 2010.

Furthermore, during the second quarter ended June 30, 2010, 58,500,000 shares of common stock were issued of which 30,000,000 restricted shares were issued related to a settlement agreement, and 28,500,000 free trading shares were issued to Big Apple Equities, LLC for investor relations services. Therefore, the issuance of these shares increased the Company’s issued shares by approximately 2.5%.

As previously announced, Metiscan will be hosting a nationwide teleconference on Wednesday, September 1, 2010 at 4:15 PM (Eastern Daylight Time) to update the financial community on points of interest that affect Metiscan and its shareholders. Space is limited on the call-in lines for this national teleconference, therefore in order to participate please call 407-389-5900 and ask for investor relations to make a reservation. If you have a particular question for the Company’s officers, please email questions in advance to [email protected].

About Metiscan, Inc.

Metiscan, Inc. (Metiscan) (PINKSHEETS: MTIZ) is the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services. Metiscan manages all aspects of its subsidiaries and is currently pursuing acquisitions that complement its subsidiaries’ operations. Metiscan’s subsidiaries include FirstView EHR, Inc., Taptopia, Inc., Schuylkill Open MRI, Inc., Shoreline Employment Services, Inc. For more information visit www.metiscan.com

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan’s actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law. 

Click here to see all recent news from this company

SAN FRANCISCO, CA–(Marketwire – August 25, 2010) –  WCG, a global communications company offering integrated creative, interactive and marketing communications services primarily to healthcare clients, today announced it won seven Awards of Excellence from the Communicator Awards, a leading international awards program honoring creative excellence in communications. The Award of Excellence is the highest honor in the competition, given to those entries that demonstrate “best in the field.”

The Communicator Awards are judged by the International Academy of the Visual Arts, a select and invitation-only group of leading professionals representing the best in media, communications, advertising, creative and marketing. Now in its 16th year, the awards competition had more than 9,000 entries from agencies of all sizes.

“This achievement is the result of our laser focus on putting creativity at the core of all we do so that we deliver the most impactful messaging — conceptually, visually and strategically,” said WCG’s Chief Creative Officer Paulo Simas. “I believe the strong combination of creative and strategy is foundational to a company’s success because creativity is innovation. And nothing catapults an organization like true innovation.”

WCG won the following Awards of Excellence:

• Perlegen — MammaPLUS ( logo)
• PEAK Surgical — PlasmaBlade ( packaging)
• Omnicell — ASHP Omnicell Apparel ( apparel)
• Viveve — Start the Conversation ( campaign)
• Elan — Elan Excellence ( pharmaceuticals)
• Medtronic — The 360 Suite ( biotechnology)
• Medtronic — Find the AAAnswers ( social responsibility)

About WCG

WCG is led by Chairman & CEO Jim Weiss, who was named to PRWeek’s Power List for 2010. The company also recently earned the distinction of North American Agency of the Year by the Holmes Report.

WCG’s mission is to create the positive future of communications by focusing on the corporate, product marketing and communications needs of the world’s leading companies.

Serving clients from offices in San Francisco, New York, Chicago, Washington, D.C., Austin and London, WCG’s seasoned professionals specialize in branding, design, digital, interactive, social and traditional marketing, corporate and product PR, media, investor and advocacy relations, clinical trial recruitment and grassroots direct-to-patient communications campaigns.

For more information, please visit www.wcgworld.com.

KANKAKEE, IL–(Marketwire – August 25, 2010) – Riverside Medical Center, a leading provider in the Chicago south suburbs hospital network, now offers a new way to stay connected to loved ones and friends during their stay in the hospital.

Under Riverside’s website features, located at www.RiversideMC.net, loved ones logging in online can simply click on the red email a patient button to get started. From there, friends and relatives can send an electronic message to a patient being treated within the Riverside Illinois healthcare system. Messages will be delivered by a Riverside volunteer Monday through Friday during business hours (8 a.m. to 5 p.m.). This service is offered as a courtesy to all Riverside patients and their families.

Additional Riverside online features include bill payment, nursery and scheduling. Patients and loved ones can also shop, check maternity registration, browse the news room and look for upcoming events at Riverside.

In an effort to provide more efficient service, Riverside Medical Center volunteers will deliver all email messages Monday – Friday during normal business hours at Riverside’s Kankakee hospital facilities. Delays in delivery may occur during weekends and holidays. Riverside Medical Center will make every effort to deliver your message promptly but cannot guarantee delivery. If a patient has been discharged or has opted to stay anonymous during their stay at Riverside Medical Center, message will be discarded.

This e-mail service should not be used for any confidential communication and is solely for the purpose of sending encouragement to patients in the hospital. Emails containing information of a personal nature or ones including any medical or diagnostic information should not be sent via this method. 

All messages will be read and printed by Riverside Medical Center volunteers. Inappropriate messages, including business solicitations or messages containing offensive or obscene language, etc. will be discarded at the discretion of the volunteers.

Unfortunately, the e-mail service can only receive and deliver messages at this time. The system cannot send a response from the patient or provide outgoing e-mail services for patients.

To learn more about the patient e-mail service, or for more information about other quality services offered by Riverside Medical Center, visit www.RiversideMC.net or call (815) 933-1671.

Click here to see all recent news from this company

BRENTWOOD, MO–(Marketwire – August 24, 2010) –  Scrubs & Beyond is proud to introduce a new line of medical scrubs exclusive to their already amazing selection. The David After Dentist (DAD) scrubs were inspired from the video seen online of David after a visit to his dentist. This video became so popular it was nominated for a Webby Award in the category of Best Viral Video. With scrub tops, scrubs pants and a scrub jacket to choose from, you can outfit yourself with your favorite DAD scrubs.

Most of us have seen the video where David is in the back seat of his Dad’s car, completely out of it after having a tooth pulled. During the video he can be seen asking “is this real life?”, which is the saying that DAD has chosen to run with. Scrubs & Beyond has placed the DAD logo and the saying on their new line of scrubs. David After Dentist unisex cargo scrub pants are a classic fit with drawstring waist and cargo pocket with cell phone slot. DAD unisex scrub tops feature a chest pocket with a pencil slot and stethoscope loop. This top comes in sizes up to 5X. If you are looking for a top with great value and quality construction, this one is for you.

In addition to the scrub pants and scrub top, Scrubs & Beyond also has a scrub jacket featured in the DAD lineup. Featuring two patch pockets, one cell phone pocket and knit cuffs, you are sure to love this jacket. With a snap front cardigan design and round neck, this is one of the best scrub jackets you can find. The DAD scrubs are made with the kind of quality that Scrubs & Beyond demands in their products. 

The best thing about these scrubs is that they come in a variety of thirty-two colors. Chocolate, new eggplant, dandelion, Malibu blue, aloe, shocking pink and orchid are just a few of the popular colors. Whatever color you want, you are sure to find it with that many colors to choose from. Scrubs & Beyond and David After Dentist make a great pairing with this new line of scrubs. Check out for yourself just how great this combination can be by visiting www.ScrubsandBeyond.com and buying a pair today!

Click here to see all recent news from this company

GLEN ELLEN, CA–(Marketwire – August 24, 2010) –  The DAISY Foundation is encouraging nurses seeking to impact and improve treatment of patients with auto-immune diseases and cancer to apply for a research or evidence-based practice project grant awarded by the foundation. The Fall deadline to submit a letter of intent for the J. Patrick Barnes Research Grant is September 3, 2010.

The foundation offers two types of research grants: research grants of up to $5,000 for projects that involve clinical research studies that directly benefit patients and/or families; and evidence-based practice grants of up to $2,000 that use patient-focused data to study and develop improved nursing practices. 

For the first time this year, successful applicants will also be allowed to apply for subsequent funding to share their findings at professional conferences. This funding will provide grantees with up to $2,000 for expenses and fees for attending or presenting at a professional conference. 

The DAISY Foundation provides these grants to support registered nurses who continually evaluate their practice, seek answers to clinical questions in an effort to improve their practice, and change their practice based on evidence and evaluation of that change. 

The DAISY Foundation encourages nurses who have research/EBP experience, as well as those who do not have experience to apply. Additional information and the grant applications are available at www.DAISYfoundation.org. 

The DAISY Foundation was established in 1999 by the family of J. Patrick Barnes, who died from complications of Idiopathic Thrombocytopenic Purpura (ITP) at the age of 33. Having been touched by the remarkable care, clinical skills and compassion demonstrated by nurses during Patrick’s illness, the Barnes family established the Foundation to recognize and support exceptional nurses around the country. The Foundation has three primary programs: the DAISY Award for Extraordinary Nurses, which recognizes the outstanding daily work of nurses in more than 650 hospitals throughout the United States, the J. Patrick Barnes Research Grant, and the newly introduced DAISY Faculty Award program. 

Click here to see all recent news from this company

ALEXANDRIA, VA–(Marketwire – August 24, 2010) –  The American Diabetes Association is extremely disappointed by the federal district court decision yesterday blocking the federal government from funding research involving embryonic stem cells. 

President Obama’s Executive Order in March of 2009 assisted advancement of stem cell research by lifting existing restrictions on the use of embryonic stem cells, while maintaining strict ethical guidelines. Even prior to that Order, federal funding of stem cell research was permitted on a limited number of previously-existing stem cell lines.

“This is a major setback for medical research, in particular, research towards a cure for diabetes,” said Richard Bergenstal, MD, President, Medicine & Science, American Diabetes Association. “This decision stands as a roadblock to research that has shown great promise in finding a cure for diabetes and treating its complications.”

Stem cell research has the potential to save and significantly improve the lives of the nearly 24 million Americans with diabetes who face its many complications including heart disease, amputation and blindness. The American Diabetes Association has extensively advocated for stem cell research, which holds the promise of accelerating medical advancements in many fields. “We will work with other concerned organizations to find a way to remove this barrier to scientific progress,” said Bergenstal.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

CHICAGO, IL–(Marketwire – August 24, 2010) –  As the back-to-school season approaches, students and parents shouldn’t forget about health insurance after budgeting for tuition, books, and other school costs. Students who face a temporary gap in coverage or don’t have any health insurance should explore their options in the individual market.

Though health reform will allow full-time students to stay on their parents plan until age 26, this won’t go into effect for millions until next year, leaving many students without coverage.

Students facing a gap in coverage. For students who are just going to face a gap in coverage for a few months, they should look into purchasing a short term health insurance policy. Short term plans are very inexpensive and cover emergency visits.

Students without health insurance. There are many students who will be going to college this fall and are required by their university to purchase health insurance. While many schools offer coverage, it is usually best and cheaper to purchase an individual health insurance policy from an insurance company.

As for cost, individual policies tend to be cheaper because young adults are in good health. An individual plan also offers more comprehensive doctor and hospital networks — university plans frequently have a strict list of covered health care providers.

Another great benefit of individual health plans for students is portability. Even after graduation, an individual health insurance policy can be kept throughout their early professional career.

“Students in need of health coverage can use GoHealthInsurance.com to quickly compare plans from different companies easily with our Quote Engine,” said Michael Mahoney, Director of Consumer Markets at GoHealthInsurance.com. “It’s never a good idea to go without coverage, and students will be surprised at how affordable health insurance can be.”

About GoHealthInsurance

GoHealthInsurance.com makes buying health insurance simple. GoHealthInsurance explains health coverage options in plain English, provides free health insurance quotes, connects shoppers with local agents, and helps consumers choose plans that meet their health and budget needs.

Click here to see all recent news from this company

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Aug. 24, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (“ALDA” or “the Company”) is monitoring reports of new “Superbugs” that are highly resistant to nearly all antibiotics, including penicillin-like antibiotics that possess broad spectrum antibacterial properties and are typically used as a last resort. The new strains of antibiotic-resistant E. coli and Klebsiella were created when genetic material that codes for an antibiotic-digesting enzyme was incorporated from other species. Such genetic “swapping” is common among bacteria and is a major cause of antibiotic resistance. Although primarily observed in Pakistan, India and the UK, similar infections have been reported in US, Canada, Australia and the Netherlands and international researchers are concerned that these new strains could become a major global health problem.

To reduce the spread of these bacteria, health authorities are recommending proper hand hygiene and disinfection procedures. Dr. Terrance Owen, President & CEO comments, “Using effective hand sanitizers and disinfectant products is an important step in keeping one’s environment safe. ALDA’s products contain 70% ethanol and benzalkonium chloride which have both proven to be very effective against E. coli and other resistant bacteria, such as MRSA. Although the threatened H1N1 pandemic did not materialize, it certainly made people aware of the need for products that can reduce the transmission of infectious diseases. The lessons learned may prove to be very useful as we face ever-increasing numbers of Superbugs.”

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

TAMPA, FL–(Marketwire – August 24, 2010) – Sage North America today announced that products developed by its Healthcare Division are now part of the award-winning Sage Partner Advantage program. The Sage Healthcare Division provides electronic health records (EHR) and practice management software and services to approximately 80,000 physicians in North America. Sage business partners choosing to represent healthcare solutions now have access to a vast array of proven, successful resources and programs that will ultimately result in better overall customer service and satisfaction.

“The Sage Partner Advantage program is critical to Sage’s success as we continuously enhance service for small and midsized healthcare practices,” said Lee Horner, Senior Vice President of Sales at Sage Healthcare Division. “This strategy will enable us to grow our market share and increase our partners’ ability to deliver products and services to meet accelerated demand, and expand our go-to-market strategy.”

Sage’s business partner channel services millions of businesses across North America. By adding the Sage Healthcare Division product portfolio to the Sage Partner Advantage program, Sage business partners can more aggressively address the needs of healthcare providers with products and services to enhance their practices. The first Sage business partner to offer healthcare products under the Sage Partner Advantage program is EHR & EMR Software Solutions, LLC, a division of Alliance Solutions Group of Brandon, FL (ASG). ASG currently represents Sage Timberline Office, Sage Master Builder and Sage FAS product lines and will now offer the Sage Intergy line of products.

“Sage’s Partner Advantage program has helped ASG in every way; from business planning and development to consulting services to improving our overall customer experience,” said Mike Griffith, Managing Member at ASG. “We’re very anxious to apply the elements of the program to capitalize on new market opportunities in Healthcare.”

The launch of the Healthcare Division’s channel program is the latest addition to the award-winning Sage Partner Advantage program, which is consistently rated a 5-Star program by EverythingChannel. The program is designed to help channel partners realize greater overall business success through extensive training in sales, consulting, business leadership and product expertise; hiring assistance; direct financial support and marketing assistance programs.

According to IDC Health Insights(1), (2), Sage Healthcare Division products that include Sage Intergy and Sage Intergy EHR are recognized as leaders in the market for small, midsized and large healthcare practices for ownership confidence and fit to market needs.

“Adding Sage healthcare solutions to the Sage Partner Advantage program shows our continued commitment to our current clients, and all practices we strive to serve,” said Betty Otter-Nickerson, President of Sage Healthcare Division. “This program enables our business partners to build on the personal support Sage currently offers its healthcare clients at the practice level and will encourage an even more robust, high level of service for our clients.”

Sage channel partners will service the ambulatory healthcare market.

For more information about the Sage Partner Advantage healthcare channel network or to find out how to join, please contact [email protected] or call 866-693-7067, press option 1.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers including approximately 80,000 physicians. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, Sage Software, Sage logos and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

1. “Vendor Assessment: The Industry Short List of Electronic Health and Medical Records for Small and Midsize Ambulatory Practices,” Document # HI220502, November 2009. 

2. “Vendor Assessment: The Industry Short List of Electronic Health and Medical Records for Large Ambulatory Practices,” Document # HI220600, November 2009.

TORONTO, ONTARIO–(Marketwire – Aug. 24, 2010) – Proponents of for-profit private health care claim our public health care system is “unsustainable,” but the facts show that these claims are driven far more by ideology than real data. Canadian Doctors for Medicare’s briefing note, Health Care Sustainability, explains the issues underlying the debate about health care sustainability, and how physicians in Canada can work together to control health care costs and to improve our health care system for the benefit of all Canadians.

Canadian Doctors for Medicare (CDM) is a national, membership-based organization that believes in Canada’s publicly-funded health care system. The organization’s mission is to provide a voice for Canadian doctors who want to strengthen and improve Canada’s universal publicly-funded health care system in a way that benefits all Canadians. 

TUSTIN, CA–(Marketwire – August 24, 2010) –  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today broad availability of its 2010 Onko-Sure® Reference Guide for the Company’s USFDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test kit.

The 2010 Onko-Sure® Reference Guide is a commercially published compilation of Radient Pharmaceuticals general information and clinical studies on the Company’s Onko-Sure® IVD cancer test kit. Designed to provide oncologists, physicians and clinicians with the most current and important information for Onko-Sure®, the guide also serves as a comprehensive reference for other health care professionals, consumers and patients.

In addition to general Company information and Onko-Sure® clinical study data, RPC’s 2010 Onko-Sure® Reference Guide provides a comprehensive list of key references, resources and other published materials users can consult to better understand the medical utilities of Onko-Sure®, how healthcare providers and patients can use the test and the science behind Onko-Sure®. 

RPC’s Onko-Sure® IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test. 

According to Mr. Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, “The 2010 Onko-Sure® Reference Guide is an invaluable resource for both members of the healthcare community and patients alike, and we believe it will serve as an important educational tool that will drive broad-based adoption and use of RPC’s Onko-Sure® IVD cancer test for the diagnosis, treatment and monitoring of cancer.”

RPC’s 2010 Onko-Sure® Reference Guide is available in both print and on-line versions. Print versions can be ordered by contacting Radient Pharmaceuticals at 1-714-505-4461 or via e-mail [email protected]; and online versions are available for download by visiting the Radient Pharmaceuticals corporate website at www.Radient-Pharma.com or RPC’s Onko-Sure®-dedicated website located at www.onko-sure.com.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For information specifically related to Onko-Sure® visit www.onko-sure.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of our Onko-Sure™ In Vitro Diagnostic cancer test. Our focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Radient Pharmaceutical’s current Onko-Sure™ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com. 

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

HOUSTON, TX–(Marketwire – August 24, 2010) –  Bederra Corporation (PINKSHEETS: BEDA), a Houston, Texas-based, diversified medical services provider, discusses recent events in detail below.

The company released its June 30, 2010 quarterly financials. As mentioned in the Management Discussion part of the filings, the financials of its recent acquisition, Texas Mobile Health (TMH), were included. The company has not been able to achieve the level of sales it had anticipated due to the overall unemployment situation causing loss of insurance benefits and therefore lower patient visits to doctors. Also, the recently passed Healthcare Legislation has caused many physicians, particularly in Texas, to opt out of Medicare therefore causing TMH to lose several doctor clients. In addition to all of this, Medicare has cut back reimbursements by 30-40%.

TMH is exploring other areas of diagnostic testing services to increase sales and these areas will be discussed in future releases.

The company reported that it had received a subpoena from the SEC. The subpoena requests certain information concerning the recently reported short selling activities in the company’s common stock and historical stock issuances. Management is fully cooperating with the Commission and will provide it information that management has compiled including weekly DTC Securities Positions Reports, its most recent NOBO list, registered shareholder list, reports and information from Buyins.net and spreadsheets prepared by management together with records requested of the company’s former transfer agent. Management also reiterated that it intends to maintain its Pink Sheets Current Information status as the company’s minimum level of transparency and disclosure as it continues to grow its business internally and through acquisitions.

As previously stated, the company’s long-term goal is to become a fully reporting company and has begun this process by achieving Pink Sheet Current Status.

About Bederra Corp.
http://www.bederra.com
Bederra Corporation provides multiple modality diagnostic medical imaging services to the greater Houston area and the world famous Texas Medical Center. The Company’s business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements might not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.

LOS ANGELES, CA–(Marketwire – August 24, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) through its subsidiary, MyMedicalRecords, Inc. (www.mymedicalrecords.com), a leading provider of Personal Health Records (PHR) technology and professional document management and imaging systems, today announced the signing of a distribution agreement with Image Access Corporation, Kodak’s largest reseller of document imaging products and services. Image Access, in business for over 20 years, will sell the MMRPro electronic document management solution to hospitals, alternate care facilities and physician practices and clinics (www.mmrprovideos.com).

Robert H. Lorsch, Chairman and CEO of MMRGlobal, commented, “We are excited about Image Access joining our growing list of resellers in support of the deployment of MMRPro. Image Access through its offering of MMRPro enables its customers to take the first step toward meaningful use.”

MMRGlobal also recently announced its move to new corporate headquarters, expanding its office space by more than 300%. The offices are located in the Associated Television International building (www.associatedtelevision.com), the Company’s strategic media and advertising partner, at 4401 Wilshire Blvd. 2nd Floor, Los Angeles, California 90010. The move will enable MMRGlobal to house development resources from its technology partner, Nihilent in India. The two companies are working together in support of MMRGlobal’s worldwide expansion of its products and services, including China.

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation and initiatives, uncertainties associated with doing business internationally across borders and territories, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

MADISON, WI–(Marketwire – August 24, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced, integrated radiation therapy solutions for cancer care, announced today that General Hospital of Guangzhou Military Command of PLA has purchased the first TomoTherapy^® radiation therapy system to be installed in Southern China. The TomoTherapy treatment system will enable the hospital to provide advanced cancer care to a wide variety of patients, including those with head and neck cancers.

“In this area of Southern China, we see a large number of patients who suffer from head and neck cancers. But our aging linear accelerator technology has limited our ability to treat these patients, forcing us to refer them to other cancer centers,” said Jian Liu, president of PLA Guangzhou Hospital, which treats more than 1 million patients annually. “The TomoTherapy platform will enable us to expand our care and deliver treatments for the most complicated cases very effectively and accurately with its integrated daily 3-D imaging.”

The TomoTherapy radiation therapy system allows clinicians to provide helical image-guided, intensity-modulated radiation therapy (IG-IMRT), which has been shown to offer better dosimetric distributions when compared to traditional IMRT treatments. PLA Guangzhou will use the TomoTherapy treatment system to address complex nasopharyngeal cancer cases, in which patients can suffer significant side effects. The daily megavoltage CT (MVCT) imaging offered by the TomoTherapy treatment system will allow clinicians at PLA Guangzhou General Hospital to better monitor changes to the parotid glands, and calculate the dosage they receive. In addition, the TomoTherapy system’s innovative adaptive planning capabilities enable clinicians to quickly and easily re-plan treatment so that the dosage received is optimized over the course of treatment.

“With its plan to focus its TomoTherapy treatments on complex head and neck cancers, we believe that PLA Guangzhou General Hospital will quickly become one of the premier locations for these types of treatments in Southern China,” said Fred Robertson, CEO of TomoTherapy. “We are happy to continue our strong relationship with our distributor TomoKnife to expand access to TomoTherapy technology for the benefit of clinicians and patients throughout China.”

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms “may,” “should,” “suggests” or “indicates” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

DALLAS, TX–(Marketwire – August 24, 2010) –  Too many men have suffered in silence for too long, according to Dr. Bill Johnson, Medical Director of Innovations Medical. He wants more men to “Loose the Moobs” by leveraging modern cosmetic procedures to solve a serious problem.

Male breast fat.

“Either more men are developing flabby pecs, or men are just taking better care of themselves now,” says Dr. Johnson. “We’ve seen the interest in male breast fat reduction jump dramatically in the last year.”

Johnson’s team of technicians at Innovations medical has seen a 300% increase in the demand for this procedure over the last 3 years. “These days, I see at least one ‘moob’ patient per week,” says Johnson. “All of them want liposuction to reduce their chest fat.”

Medically, it’s called gynecomastia, but most men refer to their enlarged breasts as “moobs.” Some Hollywood glitterati have been snapped with “moobs”: Jack Nicholson, Tom Cruise, even Arnold Schwarzenegger. There are numerous YouTube videos. But no one needs to put up with it, according to Johnson.

Causes can include obesity, hormones and kidney disease, but most of the determining factors are genetic.

“A decade ago, men didn’t seek out cosmetic procedures to address their appearance, but they do now,” says Dr. Johnson. “It’s simple and effective.” Dr. Johnson’s unique “moob” liposuction takes less than one hour, and the patient is awake the entire time. “A guy can come in, have the procedure, and be back at work the next day,” says Johnson. He combines two popular lipo technologies — Tickle Liposuction and SmartLipo. The combination allows for removal of excess fat and skin tightening in the chest area.

“I want more men to take better care of themselves,” says Dr. Johnson. “Get over the hesitation and loose the moobs!”

Innovations Medical is a full-service aesthetic medical practice with locations in Dallas, Fort Worth and Grapevine, Texas. Medical Director Bill Johnson, M.D., has been treating patients in North Texas since 1984. As the name implies, Innovations Medical was the first in North Texas to offer many leading-edge technologies, including SmartLipo, Vibro Liposuction and Acoustic Wave Therapy for cellulite. www.innovationsmedical.com

Click here to see all recent news from this company

LOUISVILLE, KY–(Marketwire – August 24, 2010) –  ZirMed®, a leading national provider of revenue cycle management solutions for healthcare providers, today announced the addition of a first-of-its-kind new self-sign up capability for Patient Notebook, ZirMed’s online electronic billing and patient medical account management solution. The self-sign up function allows patients to enroll themselves to receive and pay their medical bills electronically for multiple healthcare providers in a single convenient, secure location.

With the new self-sign up feature, patients not only enjoy the convenience and privacy of enrolling for the service from the comfort of their own home, but healthcare practices also benefit from the improved workflow, reduced paperwork and cost savings of having more patients enroll in electronic bill presentment.

“Self-subscription had been a major hurdle due to HIPAA regulations and logistical concerns, but we’ve been able to overcome these challenges to offer a new level of convenience and efficiency to both the provider and the patient,” said Jim Lacy, ZirMed CFO. “As healthcare evolves into a more consumer-driven industry, this new feature demonstrates our view of giving patients more transparency into the payment process. Our approach is a fundamental step in giving patients control over their healthcare information, both financial and clinical.”

The new self-enrollment feature allows patients to sign up online to receive billing statements and pay bills at www.patientnotebook.com. Prior to this capability, office staff had to ask patients to sign up and enroll at the office. With the self-sign up feature, the office has the flexibility to continue to enroll patients or direct them to Patient Notebook to sign themselves up for this service.

For more information about Patient Notebook visit www.zirmed.com or www.patientnotebook.com.

About ZirMed:
Founded in 1999, ZirMed is a nationally recognized leader in delivering revenue cycle management solutions to healthcare providers. ZirMed enables healthcare providers to leverage the power of technology to cure administrative burdens and increase cash flow. ZirMed solutions include eligibility verification, credit/debit card processing, check processing, claims management, coding compliancy and reimbursement management, electronic remittance advice, patient statements, patient e-commerce solutions, provider credentialing, and lock box services. ZirMed solutions are designed to complement provider workflow and to provide innovative, creative and flexible solutions for healthcare’s most pressing administrative challenges. For more information about ZirMed, visit www.zirmed.com/pr. 

PLANTATION, FL–(Marketwire – August 24, 2010) –  Transax International Limited (Transax) (OTCQB: TNSX), a network solutions company for healthcare providers and health insurance companies, today reported financial results for the first half of 2010 and second quarter ended June 30, 2010.

For the quarter ending June 30, 2010 Transax generated net revenues of $1,046,429 compared to $1,093,705 in net revenues during second quarter of 2009, a 4% decrease. The decrease in revenue is due to the loss of one minor contract during the second quarter 2010 partly offset by continued growth in real-time transactions and rollout of previously announced contracts. Transaction volume was 2.3 million for the second quarter of 2010 compared to 2.1 million in the same period during 2009.

Loss from operations in the second quarter of 2010 was $418,904 compared with a $243,988 loss during the same period in 2009. Net loss for the second quarter of 2010 was $975,480 compared with a net loss in the second quarter of 2009 of $3,442,588. The decrease in net loss is principally due to a decrease in non cash items related to derivative liabilities expenses.

For the quarter ending June 30, 2010, the Company incurred $1,465,333 in operating expenses compared to $1,337,693 during the same period in 2009. The increase in expenses was attributed to significant increases in cost of product support services together with general and administrative expense increases in complying the Company products to new government regulations in Brazil.

For the six months ended June 30, 2010 revenues increased by 1% to $2,069,261 from $2,046,023 during the same period in 2009. The loss of one customer during the period was partially offset by revenues from new customers during the period. The Company recorded an operational loss of $938,180 for the six months ending June 30, 2010 compared to operational loss of $561,171 for the six months ending June 30, 2009. Net loss for the first six months of 2010 was $1,367,493 compared to a net loss of $3,721,815 for the same period in 2009.

At the end of the second quarter 2009 the Company had over 20,150 solutions installed in Brazil including 3,125 Point of Sales (POS) Solutions, 16,350 operational WEB solutions and 1,870 Interactive Voice Response (IVR) solutions with the balance of PC and Server solutions installed in medical laboratories. During the six month period ending June 30, 2010 the company installed over 5,000 WEB solutions to medical provider locations to support future roll out and revenue growth.

In announcing the results Stephen Walters, President & CEO, stated, “Transaction volumes have increased steadily during 2010 recording a 11% annual increase. The company installed 1,250 solutions during July 2010 and recorded over 850,000 for the month of July 2010. Additional roll out of solutions to increase revenues and reduction in operating costs is the main target of the company for the second half of the year.”

About Transax International Limited

Transax International is an emerging network solutions provider for the healthcare sector. Utilizing its proprietary MedLink™ technology, Transax provides a service similar to credit card processing for the health insurance and providers industries. A transaction consists of: approving eligibility, authorization, auto-adjudication of the health claim and generating the claim payable files — provided instantaneously in “real time” — regardless of method of claim generation.

Transax’s solutions have been proven to significantly decrease health insurance claim expenditures and healthcare provider costs. Based in Plantation, Fl, Transax maintains a major operations office in Rio de Janeiro, Brazil, with approximately 45 staff and a Sales Office in Sao Paulo, Brazil. The Company has contracts in place with major health insurers in Brazil and currently undertakes approximately 800,000 transactions per month.

SAFE HARBOR STATEMENT: “THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, THE COMPANY’S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE ‘SAFE HARBOR’ PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.”

MELVILLE, NY–(Marketwire – August 24, 2010) – FONAR Corporation (NASDAQ: FONR), the Inventor of MR Scanning™, announced the purchase of an UPRIGHT® Multi-Position™ MRI by a distinguished Board Certified radiologist in Florida. He is the owner operator of two multi-modality imaging centers equipped with MRIs.

“He was initially considering purchasing a 3 Tesla lie-down MRI,” said Raymond V. Damadian, M.D., president and founder of FONAR Corporation, “but decided instead to buy the FONAR UPRIGHT® Multi-Position™ MRI when he became aware of its many unique imaging capabilities.”

As he explained, “many of the physicians who send patients to our multi-modality medical imaging practices are surgeons who perform spine surgery. It is a very important specialty in medical practice since the second most common reason today, after the common cold, for visiting a doctor’s office is ‘back pain.’

“Each year, 40 to 60 percent of American adults suffer from chronic back pain. More than one million spine surgery procedures are performed annually, with medical costs to treat back pain approaching $24 billion per year. (http://nyp.org/news/hospital/spine-fusion-surgery.html).

“As of 2007, approximately 9 million of the 27.5 million MRIs performed each year in the U.S. are of the spine.

“Accordingly,” he said, “aware that the number one priority of all my referring spine surgeons is the best possible outcomes for their patients, I became convinced that the only technology capable of maximizing the surgical outcomes for my physician senders was to assure that they were able to see ALL of the pathology they had to address, not just part of it from a lie-down scanner in which the body weight has been removed.”

“The spine is a difficult region of anatomy for the surgeon,” he continued, “because as the principal weight-bearing structure of the body it shows its wear and tear degeneration early on. Consequently, degenerative changes of the spine are a normal concomitant of the aging process. This reality, however, from the surgeon’s perspective, can be confounding. Does he, for example, surgically address the degenerative loss of disc height and neural foramina narrowing at L1/2, the ‘spondy’ at L2/3, or the disc herniation at L4/5? It is evident that if a vertebral segment not responsible for the patient’s pain is subjected to surgery, the pain will not improve and there is even the risk that the patient’s clinical condition and pain could be made worse by carrying out surgery on the wrong segment.”

“Consequently,” he stated, “the key to a good surgical outcome is the success with which the degenerative changes responsible for the patient’s pain, are successfully separated from the degenerative changes that are not causing the patient’s pain, so that only those segments responsible for the patient’s pain are operated on.”

“Of all the commercially available MRI scanners,” he said, “the FONAR UPRIGHT® Multi-Position™ scanner is the only MRI that meets this need. What FONAR’s UPRIGHT® Multi-Position™ weight-bearing technology makes possible that no other scanner can accomplish is the ability for the radiologist to ask the patient to put himself in the position (standing, sitting, lateral bending, flexion, extension, rotation, etc.) that generates his pain, which no other scanner can do. A picture can then be taken with the patient in his actual pain generating position and then compared to a picture of the patient in an adjacent non-pain-generating position so that the correct pain generating anatomy can be unequivocally identified. This permits the surgeon to address only the anatomy segment generating the patient’s pain, and enables him to avoid surgery on segments not involved in pain generation. The ultimate result is excellent outcomes for the surgeons and their patients.

“A recumbent non-weight-bearing single-position MRI simply cannot meet this need. We see it as a critical need, if we are going to be successful in improving surgical outcomes for our patients.

“Also important to our surgeons is their ability to see their surgical results post-operatively, which the FONAR UPRIGHT® Multi-Position™ MRI can accomplish and the conventional MRI cannot. In the event of a less than optimal surgical outcome, or even an outcome that deteriorates over time, it is critical for the surgeon to be able to see post-operatively any hardware devices he may have implanted (e.g. artificial discs, pedicle screws, fusion rods, etc.) in order to address any surgical results that require further attention. Consequently, being able to clearly visualize installed implants in the post-operative spine is key for the surgeon to be able to address any further needs the patient might have.

“The FONAR scanner at 0.6 T meets this need of the surgeon since it is uniquely spared the magnetic susceptibility image artifacts that the 1.5 T and 3.0 T lie-down scanners generate. The implant artifacts obliterate the anatomy of the vertebral segments that are being imaged and make it impossible for the surgeon to discern the source of any persisting post-operative symptoms or pain that the patient might be experiencing.”

He also expressed the need to be able to provide the unique imaging capabilities provided by the FONAR UPRIGHT® scanner to distinguish his radiology practice from competing radiology centers. “The FONAR UPRIGHT® Multi-Position™ MRI is the quintessence of the technology for breaking existing referral patterns. By offering the unique capabilities of the FONAR UPRIGHT® MRI,” he stated, “and thereby distinguishing our radiology practice from competitors who market the same ‘me-too’ products, we would be bringing to our community a ‘Center of Excellence’ for imaging the spine. In so doing, we would be establishing for our community a COMPLETE radiology imaging service that could not be obtained elsewhere. Ultimately this would generate business for all of our imaging modalities. By offering a COMPLETE imaging service that includes all of FONAR’s new UPRIGHT® imaging technologies that are not available anywhere in our community, we would achieve ‘One Stop Shopping’ for our patients to address all of their imaging needs.”

“An example of one of the many unique imaging capabilities made possible by the FONAR UPRIGHT® Multi-Position™ fully weight-loaded imaging,” he continued, “is the ability to image, without x-ray, the 400,000 scoliosis patients that must be imaged UPRIGHT® 2 to 3 times per year to monitor their scoliosis treatment. The elimination of x-ray avoids the 70% increased incidence of breast cancer reported by the National Cancer Institute to be the result of the standard annual x-ray examinations of these patients (National Cancer Institute, www.cancer.gov and M. Morin Doody et al. Spine, 8/15/2000, Vol. 25, #16).

“Another example is the ability to scan small children and infants seated on their mother’s lap as they watch their favorite cartoon on the flat screen TV shipped with the system. This greatly reduces the number of children requiring anesthesia when MRI is needed and is a valuable feature of the FONAR UPRIGHT® that we will be bringing to our pediatric community.

“In addition, the ability to scan UPRIGHT® the large population of women suffering from the PFD (pelvic floor dysfunction) symptoms of cystitis, urinary incontinence and bowel dysfunction is another valuable benefit of the UPRIGHT® MRI. Because of the FONAR UPRIGHT® MRI, the cause of these dysfunctions can now be definitively shown on the MRI images and successfully treated surgically. These pelvic floor dysfunctions are the result of the cystic, vaginal, and rectal prolapses generated by the pelvic floor stresses of childbirth. They are readily visualized,” he said, “by the FONAR UPRIGHT® MRI but are not readily diagnosed by the gynecologist employing the conventional lie-down pelvic examination.”

“There are also now,” he stated, “a large number of patients suffering the consequences of automobile whiplash injuries (Brain Injury, July 2010; 24[7-8]:988) and the ‘fallen’ cerebellar tonsil syndrome (Chiari or CTE; cerebellar tonsil ectopia) that results. The ‘fallen’ cerebellar tonsils require UPRIGHT® imaging to be seen and cannot satisfactorily be visualized by a conventional lie-down MRI. It is another unique need met by the FONAR UPRIGHT® MRI capability.”

“In addition, there is now the power using FONAR’s new cerebro-spinal fluid (CSF) flow technology,” he said, “to create cinés of cerebro-spinal fluid flow, and in particular, to be able to create cinés of this CSF flow in the upright position so that the adequacy of CSF flow into the upright brain can be quantified and visualized. Imaging patients in the upright position assures there are no dynamic impairments to this vital cerebro-spinal function and enables their correction if it exists. With the recent increased incidence of automobile whiplash injuries (C.S.B. Galasko et al., J. Musc-Skel. Pain 2000, Vol. 8, No. 1-2, p. 15) and the cerebellar tonsillar ectopias (CTE) that result, it is critical to identify this pathology as soon as it occurs so it can be addressed before more dire consequences occur.”

“The ‘Thoracic Outlet Syndrome (TOS)’ is yet another symptom complex,” he further stated, “that can benefit from FONAR’s UPRIGHT® imaging technology. The ‘TOS’ patients can now be scanned upright in the FONAR UPRIGHT® Multi-Position™ MRI and placed in the positions that compress the brachial plexus and subclavian artery so that the pathologic anatomy causing the compressions can be visualized and specifically addressed surgically when necessary.

“There is also now the newly recognized Pelvic Congestion Syndrome (PCS) that needs the benefits of UPRIGHT® imaging. PCS is a symptom complex in women where pelvic pain arises secondary to venous congestion and pelvic varicosities. Prolonged standing, in particular, gives rise to the pain and has to be diagnostically distinguished from other causes of pelvic pain such as fibrosis and endometriosis. Placing the patient upright in the FONAR UPRIGHT® Multi-Position™ MRI can readily visualize the pain generating venous congestion and pelvic varicosities so that a definitive diagnosis can be achieved and treatment administered.

“Another valued application for the FONAR UPRIGHT® Multi-Position™ MRI scanner is its potential for evaluating the ‘runner’s knee’ syndrome, i.e. the Patella Femoral Pain Syndrome (PFPS). In the light of the current day practice of daily running exercise to achieve aerobic fitness, accurate diagnosis of the fully weight-loaded ‘runner’s knee’ in different degrees of flexion and extension, including single leg squats, is a growing need. The FONAR UPRIGHT® Multi-Position™ MRI makes possible the visualization of the cartilage contact surfaces of the knee, namely, the miniscal and articular cartilage surfaces that support the body’s weight and enable smooth motion of this dynamic weight-supporting structure. This enables the risks from any long-bone malalignments or patella tracking dysfunctions that give rise to ‘runner’s knee’ to be assessed and addressed before they result in a permanent debilitating osteoarthritis. University biomechanical specialists have recently been conducting research using the FONAR UPRIGHT® Multi-Position™ MRI to explore and better define the ‘runner’s knee’ condition and the ‘patellar tracking’ abnormalities that can aggravate it. The FONAR UPRIGHT® cinés of the fully weight-bearing knee make the multi-position dynamic visualization of ‘runner’s knee’ and the diagnostic analysis of it a reality.

“Particularly valuable to me as a radiologist,” he continued, “is FONAR’s new Correlated Slice Profile (CSP) technology. It takes the FONAR Multi-Position™ MRI technology to a new level. With FONAR’s Correlated Slice Profile (CSP) technology, each slice of a 15-slice multi-slice MRI scan of the spine appears on the radiologist’s screen (or film) adjacent to the images of the other positions of the same slice. By re-centering the slices prior to the image acquisition of a new position, the slices of each position scan remain correlated despite any shifts of the body axis that result from changes in body position. The radiologist can then view each slice of the scan in all 3 of its weight-bearing positions, neutral sit, flexion and extension, alongside the same slice from the recumbent position. This enables the radiologist to easily track a given pathology (e.g. a disc herniation or spondylolisthesis) through all of its four positions so the surgeon can be advised of the full range the patient’s spinal pathology (e.g. disc herniation, spondylolisthesis) traverses during the daily range of his/her body positions. By so doing, the surgeon sees the FULL EXTENT of the pathology he must address to get a good outcome.

“I agree with FONAR’s German customer who just ordered their 4^th FONAR UPRIGHT® MRI because of their business success with FONAR’s new technology (Press Release, FONAR Corporation, August 3, 2010). We agree with them that FONAR’s UPRIGHT® Multi-Position™ MRI is indeed setting a new MRI ‘standard of care’ for a wide range of medical applications.”

For investor and other information visit: www.fonar.com.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, pMRI™, Dynamic™, Multi-Position™, True Flow™, The Proof is in the Picture™, Spondylography™ Spondylometry™ and Upright Radiology™ are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company’s financial results may be found in the company’s filings with the Securities and Exchange Commission.

CLARK, NJ–(Marketwire – August 24, 2010) –  HealthEd, a specialized agency focused on turning health education into positive outcomes, today announced the appointment of Raffaele Piemonte as chief technology officer (CTO). With the addition of Piemonte to the company’s executive team, HealthEd aims to position itself for further growth in this year’s fourth quarter and in 2011.

“We’re committed to improving people’s lives and helping our clients find new and engaging ways to do that,” said Roy Broadfoot, CEO and president of HealthEd. “Digital solutions will be critical to achieving that goal. Raffaele’s extensive experience in developing original applications, combined with his deep understanding of the integration of IT, business, and operational needs, perfectly aligns with the company’s mission of creating a healthier world.”

As CTO, Piemonte will be responsible for developing and executing HealthEd’s technology strategy and leading its technology team. Mr. Piemonte brings to the growing company a variety of IT expertise in several areas, including software architecture, identity management, project life cycle management, and business process optimization. Piemonte’s appointment signals the company’s commitment to making digital marketing integral to its growth and development.

Previously, Mr. Piemonte was with KPMG as director of application integration services. His prior experience includes CTO positions with IEG-Sponsordirect, Riverblade, and Ingredients.com.

Mr. Piemonte’s experience also includes presenting at numerous conferences and penning several articles for various tech journals as well as coauthoring “Developing Applications Using Outlook 2000, CDO, Exchange and Visual Basic,” a comprehensive reference guide for IT professionals for building program applications in collaboration with Microsoft platforms and tools.

About HealthEd
HealthEd is a specialized agency that uses education to help people develop the knowledge, skills, motivation, and confidence to manage important health decisions and activities and ultimately achieve better health outcomes. For more information about HealthEd and the services we offer, please visit http://www.HealthEd.com or contact Anita St. Clair, chief client development officer, at 908-389-2133.

Click here to see all recent news from this company